Inactive Ingredient Search for Approved Drug Products
You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with View All
| Quarter | Inactive Ingredient | Route of Administration | Dosage Form | Maximum Potency per unit dose | Maximum Daily Exposure | Status | |
|---|---|---|---|---|---|---|---|
| Q3 2021 | ACACIA | ORAL | POWDER | 1231.00 mg | Correction | ||
| Q4 2021 | ACACIA | ORAL | POWDER | 800.00 mg | Correction | ||
| Q3 2021 | ISOOCTYL ACRYLATE/ACRYLAMIDE/VINYL ACETATE COPOLYMER, KOLLIDON VA 64 POLYMER | TOPICAL | SPONGE | 5.40 %w/w | Correction | ||
| Q4 2021 | ACRYLATES COPOLYMER | TOPICAL | SOLUTION | 5.40 %w/w | Correction | ||
| Q3 2021 | CITRIC ACID MONOHYDRATE | BUCCAL | FILM, SOLUBLE | 0.69 mg | Correction | ||
| Q4 2021 | ANHYDROUS CITRIC ACID | BUCCAL | FILM, SOLUBLE | 3 mg | Correction | ||
| Q3 2021 | ERYTHROSINE SODIUM ANHYDROUS | ORAL | CAPSULE | 0.42 mg | Correction | ||
| Q4 2021 | ERYTHROSINE SODIUM ANHYDROUS | ORAL | CAPSULE | 0.01 mg | Correction | ||
| Q3 2021 | FLAVOR MIXED FRUIT PFC-9970 | ORAL | GRANULE, FOR SUSPENSION | 350.00 mg/ 5.00 ml | Correction | ||
| Q4 2021 | FLAVOR MIXED FRUIT PFC-9970 | ORAL | GRANULE, FOR SUSPENSION | 17.50 mg/ 5.00 ml | Correction | ||
| Q3 2021 | GLYCERIN | TOPICAL | CLOTH | 50.00 mg | Correction | ||
| Q4 2021 | GLYCERIN | TOPICAL | CLOTH | 0.05 mg/mg | Correction | ||
| Q3 2021 | HYDROGENATED SOYBEAN LECITHIN | INTRAVENOUS | INJECTION, SUSPENSION, LIPOSOMAL | 9.58 mg/ml | Correction | ||
| Q4 2021 | HYDROGENATED SOYBEAN PHOSPHATIDYLCHOLINE | INTRAVENOUS | INJECTION, SUSPENSION, LIPOSOMAL | 9.58 mg/ml | Correction | ||
| Q3 2021 | HYDROXYPROPYL CELLULOSE (1600000 WAMW) | ORAL | TABLET, CHEWABLE | 20 mg | Correction | ||
| Q4 2021 | HYDROXYPROPYL CELLULOSE (1600000 WAMW) | ORAL | TABLET, CHEWABLE | 10 mg | Correction | ||
| Q3 2021 | HYPROMELLOSE 2208 (100000 MPA.S) | ORAL | TABLET, FILM COATED | 536.80 mg | Correction | ||
| Q4 2021 | HYPROMELLOSE 2208 (100 MPA.S) | ORAL | TABLET, FILM COATED | 10.00 mg | Correction | ||
| Q3 2021 | HYPROMELLOSE 2208 (3 MPA.S) | ORAL | TABLET, EXTENDED RELEASE | 184.25 mg | Correction | ||
| Q4 2021 | HYPROMELLOSE 2208 (3 MPA.S) | ORAL | TABLET, EXTENDED RELEASE | 85.50 mg | Correction | ||
| Q3 2021 | OPADRY YS-1-8325 BEIGE | ORAL | TABLET | 48 mg | Correction | ||
| Q4 2021 | OPADRY YS-1-8325 BEIGE | ORAL | TABLET | 16.00 mg | Correction | ||
| Q3 2021 | POLYETHYLENE GLYCOL 8000 | ORAL | TABLET, MULTILAYER, EXTENDED RELEASE | 4.30 mg | Correction | ||
| Q4 2021 | POLYETHYLENE GLYCOL 8000 | ORAL | TABLET, MULTILAYER, EXTENDED RELEASE | 2.50 mg | Correction | ||
| Q3 2021 | POLYVINYL ACETATE | ORAL | TABLET | 19.24 mg | Correction | ||
| Q4 2021 | POLYVINYL ACETATE | ORAL | TABLET | 7.00 mg | Correction | ||
| Q3 2021 | PPG-11 STEARYL ETHER | TOPICAL | AEROSOL, FOAM | 5.00 %w/w | Correction | ||
| Q4 2021 | POLYPROPYLENE GLYCOL 11 STEARYL ETHER | TOPICAL | AEROSOL, FOAM | 5.00 %w/w | Correction | ||
| Q3 2021 | PPG-11 STEARYL ETHER | TOPICAL | SUSPENSION | 16.00 %w/w | Correction | ||
| Q4 2021 | POLYPROPYLENE GLYCOL 11 STEARYL ETHER | TOPICAL | SUSPENSION | 16.00 %w/w | Correction | ||
| Q3 2021 | PPG-15 STEARYL ETHER | TOPICAL | GEL | 2.00 %w/w | Correction | ||
| Q4 2021 | POLYPROPYLENE GLYCOL 15 STEARYL ETHER | TOPICAL | GEL | 2.00 %w/w | Correction | ||
| Q3 2021 | PPG-15 STEARYL ETHER | TOPICAL | OINTMENT | 15.00 %w/w | Correction | ||
| Q4 2021 | POLYPROPYLENE GLYCOL 15 STEARYL ETHER | TOPICAL | OINTMENT | 15.00 %w/w | Correction | ||
| Q3 2021 | PPG-15 STEARYL ETHER | TOPICAL | SUSPENSION | 16.00 %w/w | Correction | ||
| Q4 2021 | POLYPROPYLENE GLYCOL 15 STEARYL ETHER | TOPICAL | SUSPENSION | 16.00 %w/w | Correction | ||
| Q3 2021 | POVIDONE K15 | TOPICAL | SYSTEM | 280.00 mg | Correction | ||
| Q4 2021 | POVIDONE K90 | TOPICAL | SYSTEM | 280 mg | Correction | ||
| Q3 2021 | POVIDONE K27 | ORAL | TABLET, EXTENDED RELEASE | 10.00 mg | Correction | ||
| Q4 2021 | POVIDONE K27 | ORAL | TABLET, EXTENDED RELEASE | 10.00 mg | Correction | ||
| Q3 2021 | PROPYLENE GLYCOL | TOPICAL | CLOTH | 15.00 mg | Correction | ||
| Q4 2021 | PROPYLENE GLYCOL | TOPICAL | CLOTH | 0.02 mg/mg | Correction | ||
| Q3 2021 | SCOTCHPAK 1022 | TRANSDERMAL | SYSTEM | 364.46 mg | Correction | ||
| Q4 2021 | SCOTCHPAK 9755 | TRANSDERMAL | SYSTEM | 364.46 mg | Correction | ||
| Q3 2021 | SODIUM BENZOATE | ORAL | TABLET, COATED | 9.00 mg | Correction | ||
| Q4 2021 | SODIUM BENZOATE | ORAL | TABLET, COATED | 0.20 mg | Correction | ||
| Q3 2021 | SODIUM HYDROXIDE | ORAL | CAPSULE, EXTENDED RELEASE | 0.03 mg | Correction | ||
| Q4 2021 | SODIUM HYDROXIDE | ORAL | CAPSULE, EXTENDED RELEASE | 0.01 mg | Correction | ||
| Q3 2021 | SODIUM PHOSPHATE, DIBASIC | ORAL | SUSPENSION | 8.00 mg/ 1.00 ml | Correction | ||
| Q4 2021 | SODIUM PHOSPHATE, DIBASIC | ORAL | SUSPENSION | 4.50 mg/ 1.00 ml | Correction | ||
| Q3 2021 | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | INTRATHECAL | INJECTION, SOLUTION | 0.01 %w/w | Correction | ||
| Q4 2021 | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | INTRATHECAL | INJECTION, SOLUTION | 0.01 %w/v | Correction | ||
| Q3 2021 | SODIUM SULFATE | OPHTHALMIC | SUSPENSION | 1.20 %w/w | Correction | ||
| Q4 2021 | SODIUM SULFATE | OPHTHALMIC | SUSPENSION | 1.20 %w/v | Correction | ||
| Q3 2021 | SORBITOL | NASAL | SPRAY | 44.80 mg/ 1.00 ml | Correction | ||
| Q4 2021 | SORBITOL | NASAL | SPRAY | 6.17 mg/ 1.00 ml | Correction | ||
| Q3 2021 | SORBITOL | ORAL | SOLUTION | 18000 mg | Correction | ||
| Q4 2021 | SORBITOL | ORAL | SOLUTION | 12000 mg | Correction | ||
| Q3 2021 | STARCH | VAGINAL | TABLET | 305.00 mg | Correction | ||
| Q4 2021 | STARCH | VAGINAL | TABLET | 260.00 mg | Correction | ||
| Q3 2021 | TALC | ORAL | TABLET, MULTILAYER, EXTENDED RELEASE | 18 mg | Correction | ||
| Q4 2021 | TALC | ORAL | TABLET, MULTILAYER, EXTENDED RELEASE | 9.00 mg | Correction | ||
| Q3 2021 | .ALPHA.-TOCOPHEROL, DL- | ORAL | CAPSULE | 1.00 mg | MDE Replacement | ||
| Q4 2021 | .ALPHA.-TOCOPHEROL, DL- | ORAL | CAPSULE | 7 mg | MDE Replacement | ||
| Q3 2021 | ACACIA | ORAL | POWDER, FOR SUSPENSION | 648.00 mg | MDE Replacement | ||
| Q4 2021 | ACACIA | ORAL | POWDER, FOR SUSPENSION | 7386 mg | MDE Replacement | ||
| Q3 2021 | ACESULFAME | ORAL | SOLUTION | 4.00 mg/ 1.00 ml | MDE Replacement | ||
| Q4 2021 | ACESULFAME | ORAL | SOLUTION | 120 mg | MDE Replacement | ||
| Q3 2021 | ACESULFAME POTASSIUM | ORAL | SOLUTION | 200.00 mg | MDE Replacement | ||
| Q4 2021 | ACESULFAME POTASSIUM | ORAL | SOLUTION | 288 mg | MDE Replacement | ||
| Q3 2021 | ACESULFAME POTASSIUM | ORAL | TABLET | 27.80 mg | MDE Replacement | ||
| Q4 2021 | ACESULFAME POTASSIUM | ORAL | TABLET | 111.2 mg | MDE Replacement | ||
| Q3 2021 | ACESULFAME POTASSIUM | ORAL | TABLET, FOR SUSPENSION | 1.80 mg | MDE Replacement | ||
| Q4 2021 | ACESULFAME POTASSIUM | ORAL | TABLET, FOR SUSPENSION | 7.2 mg | MDE Replacement | ||
| Q3 2021 | ACRYL-EZE 93018509 WHITE | ORAL | TABLET | 76.68 mg | MDE Replacement | ||
| Q4 2021 | ACRYL-EZE 93018509 WHITE | ORAL | TABLET | 153.36 mg | MDE Replacement | ||
| Q3 2021 | ALCOHOL | INTRAMUSCULAR | INJECTION | 20.00 %w/v | MDE Replacement | ||
| Q4 2021 | ALCOHOL | INTRAMUSCULAR | INJECTION | 1000 mg | MDE Replacement | ||
| Q3 2021 | ALCOHOL | INTRAVENOUS | INJECTION, EMULSION | 2.85 %w/v | MDE Replacement | ||
| Q4 2021 | ALCOHOL | INTRAVENOUS | INJECTION, EMULSION | 520 mg | MDE Replacement | ||
| Q3 2021 | ALCOHOL | ORAL | SUSPENSION | 72.50 mg | MDE Replacement | ||
| Q4 2021 | ALCOHOL | ORAL | SUSPENSION | 520 mg | MDE Replacement | ||
| Q3 2021 | ALCOHOL | ORAL | SYRUP | 81.30 mg/ 1.00 ml | MDE Replacement | ||
| Q4 2021 | ALCOHOL | ORAL | SYRUP | 21000 mg | MDE Replacement | ||
| Q3 2021 | ALCOHOL | SUBLINGUAL | SPRAY | 49.60 mg/ 1.00 ml | MDE Replacement | ||
| Q4 2021 | ALCOHOL | SUBLINGUAL | SPRAY | 396.8 mg | MDE Replacement | ||
| Q3 2021 | ALCOHOL | TOPICAL | GEL, METERED | 72.60 %w/w | MDE Replacement | ||
| Q4 2021 | ALCOHOL | TOPICAL | GEL, METERED | 525 mg | MDE Replacement | ||
| Q3 2021 | ALUMINUM POLYESTER | TRANSDERMAL | FILM, EXTENDED RELEASE | 81.00 mg | MDE Replacement | ||
| Q4 2021 | ALUMINUM POLYESTER | TRANSDERMAL | FILM, EXTENDED RELEASE | 81 mg | MDE Replacement | ||
| Q3 2021 | ALUMINUM SILICATE | ORAL | TABLET, EXTENDED RELEASE | 94.00 mg | MDE Replacement | ||
| Q4 2021 | ALUMINUM SILICATE | ORAL | TABLET, EXTENDED RELEASE | 94 mg | MDE Replacement | ||
| Q3 2021 | ALUMINUM SILICATE | TOPICAL | SYSTEM | 18.90 mg | MDE Replacement | ||
| Q4 2021 | ALUMINUM SILICATE | TOPICAL | SYSTEM | 18.9 mg | MDE Replacement | ||
| Q3 2021 | ALUMINUM STEARATE | ORAL | CAPSULE, EXTENDED RELEASE | 0.40 mg | MDE Replacement | ||
| Q4 2021 | ALUMINUM STEARATE | ORAL | CAPSULE, EXTENDED RELEASE | 0.8 mg | MDE Replacement | ||
| Q3 2021 | ALUMINUM STEARATE | ORAL | TABLET | 2.80 mg | MDE Replacement | ||
| Q4 2021 | ALUMINUM STEARATE | ORAL | TABLET | 5.6 mg | MDE Replacement | ||
| Q3 2021 | AMMONIA SOLUTION | ORAL | TABLET, EXTENDED RELEASE | NA | MDE Replacement | ||
| Q4 2021 | AMMONIA SOLUTION | ORAL | TABLET, EXTENDED RELEASE | 5.9 mg | MDE Replacement | ||
| Q3 2021 | AMMONIO METHACRYLATE COPOLYMER TYPE A | ORAL | CAPSULE, EXTENDED RELEASE | 42.40 mg | MDE Replacement | ||
| Q4 2021 | AMMONIO METHACRYLATE COPOLYMER TYPE A | ORAL | CAPSULE, EXTENDED RELEASE | 63.6 mg | MDE Replacement | ||
| Q3 2021 | AMMONIO METHACRYLATE COPOLYMER TYPE B | ORAL | CAPSULE | 109.56 mg | MDE Replacement | ||
| Q4 2021 | AMMONIO METHACRYLATE COPOLYMER TYPE B | ORAL | CAPSULE | 219.12 mg | MDE Replacement | ||
| Q3 2021 | AMMONIO METHACRYLATE COPOLYMER TYPE B | ORAL | CAPSULE, EXTENDED RELEASE | 91.88 mg | MDE Replacement | ||
| Q4 2021 | AMMONIO METHACRYLATE COPOLYMER TYPE B | ORAL | CAPSULE, EXTENDED RELEASE | 178.34 mg | MDE Replacement | ||
| Q3 2021 | AMMONIO METHACRYLATE COPOLYMER TYPE B | ORAL | TABLET, FILM COATED | 8.00 mg | MDE Replacement | ||
| Q4 2021 | AMMONIO METHACRYLATE COPOLYMER TYPE B | ORAL | TABLET, FILM COATED | 32 mg | MDE Replacement | ||
| Q3 2021 | AMMONIUM CHLORIDE | ORAL | TABLET | 4.20 mg | MDE Replacement | ||
| Q4 2021 | AMMONIUM CHLORIDE | ORAL | TABLET | 8.4 mg | MDE Replacement | ||
| Q3 2021 | ANHYDROUS CITRIC ACID | INTRACARDIAC | INJECTION | 0.25 %w/v | MDE Replacement | ||
| Q4 2021 | ANHYDROUS CITRIC ACID | INTRACARDIAC | INJECTION | 22.5 mg | MDE Replacement | ||
| Q3 2021 | ANHYDROUS CITRIC ACID | INTRAMUSCULAR | INJECTION | 0.33 %w/v | MDE Replacement | ||
| Q4 2021 | ANHYDROUS CITRIC ACID | INTRAMUSCULAR | INJECTION | 22.5 mg | MDE Replacement | ||
| Q3 2021 | ANHYDROUS CITRIC ACID | INTRAVENOUS | INJECTION | 166.00 mg | MDE Replacement | ||
| Q4 2021 | ANHYDROUS CITRIC ACID | INTRAVENOUS | INJECTION | 510 mg | MDE Replacement | ||
| Q3 2021 | ANHYDROUS CITRIC ACID | ORAL | GRANULE, FOR SUSPENSION | 4.90 mg | MDE Replacement | ||
| Q4 2021 | ANHYDROUS CITRIC ACID | ORAL | GRANULE, FOR SUSPENSION | 29.4 mg | MDE Replacement | ||
| Q3 2021 | ANHYDROUS CITRIC ACID | ORAL | TABLET, CHEWABLE, EXTENDED RELEASE | 8.00 mg | MDE Replacement | ||
| Q4 2021 | ANHYDROUS CITRIC ACID | ORAL | TABLET, CHEWABLE, EXTENDED RELEASE | 12 mg | MDE Replacement | ||
| Q3 2021 | ANHYDROUS CITRIC ACID | SUBCUTANEOUS | INJECTION | 0.25 %w/v | MDE Replacement | ||
| Q4 2021 | ANHYDROUS CITRIC ACID | SUBCUTANEOUS | INJECTION | 22.5 mg | MDE Replacement | ||
| Q3 2021 | ANHYDROUS DEXTROSE | INTRAVENOUS | INJECTION | 2000.00 mg | MDE Replacement | ||
| Q4 2021 | ANHYDROUS DEXTROSE | INTRAVENOUS | INJECTION | 2700 mg | MDE Replacement | ||
| Q3 2021 | ANHYDROUS DEXTROSE | NASAL | SPRAY, METERED | 50.00 mg | MDE Replacement | ||
| Q4 2021 | ANHYDROUS DEXTROSE | NASAL | SPRAY, METERED | 200 mg | MDE Replacement | ||
| Q3 2021 | ANHYDROUS DEXTROSE | ORAL | GRANULE, FOR SUSPENSION | 2813.00 mg | MDE Replacement | ||
| Q4 2021 | ANHYDROUS DEXTROSE | ORAL | GRANULE, FOR SUSPENSION | 16878 mg | MDE Replacement | ||
| Q3 2021 | ANHYDROUS DEXTROSE | ORAL | TABLET, EXTENDED RELEASE | 15.00 mg | MDE Replacement | ||
| Q4 2021 | ANHYDROUS DEXTROSE | ORAL | TABLET, EXTENDED RELEASE | 30 mg | MDE Replacement | ||
| Q3 2021 | ANHYDROUS DIBASIC CALCIUM PHOSPHATE | ORAL | CAPSULE, DELAYED RELEASE | 381.00 mg | MDE Replacement | ||
| Q4 2021 | ANHYDROUS DIBASIC CALCIUM PHOSPHATE | ORAL | CAPSULE, DELAYED RELEASE | 381 mg | MDE Replacement | ||
| Q3 2021 | ANHYDROUS DIBASIC CALCIUM PHOSPHATE | ORAL | TABLET, FOR SUSPENSION | 101.50 mg | MDE Replacement | ||
| Q4 2021 | ANHYDROUS DIBASIC CALCIUM PHOSPHATE | ORAL | TABLET, FOR SUSPENSION | 406 mg | MDE Replacement | ||
| Q3 2021 | ANHYDROUS DIBASIC CALCIUM PHOSPHATE | SUBLINGUAL | POWDER | 10.00 mg | MDE Replacement | ||
| Q4 2021 | ANHYDROUS DIBASIC CALCIUM PHOSPHATE | SUBLINGUAL | POWDER | 30 mg | MDE Replacement | ||
| Q3 2021 | ANHYDROUS LACTOSE | ORAL | TABLET, FILM COATED | 622.21 mg | MDE Replacement | ||
| Q4 2021 | ANHYDROUS LACTOSE | ORAL | TABLET, FILM COATED | 622.21 mg | MDE Replacement | ||
| Q3 2021 | ASCORBIC ACID | ORAL | CAPSULE, EXTENDED RELEASE | 0.40 mg | MDE Replacement | ||
| Q4 2021 | ASCORBIC ACID | ORAL | CAPSULE, EXTENDED RELEASE | 0.8 mg | MDE Replacement | ||
| Q3 2021 | ASCORBIC ACID | ORAL | POWDER, FOR SOLUTION | 200.00 mg | MDE Replacement | ||
| Q4 2021 | ASCORBIC ACID | ORAL | POWDER, FOR SOLUTION | 560 mg | MDE Replacement | ||
| Q3 2021 | ASPARTAME | ORAL | TABLET, CHEWABLE, EXTENDED RELEASE | 12.00 mg | MDE Replacement | ||
| Q4 2021 | ASPARTAME | ORAL | TABLET, CHEWABLE, EXTENDED RELEASE | 18 mg | MDE Replacement | ||
| Q3 2021 | ASPARTAME | ORAL | TABLET, FOR SUSPENSION | 3.70 mg | MDE Replacement | ||
| Q4 2021 | ASPARTAME | ORAL | TABLET, FOR SUSPENSION | 14.8 mg | MDE Replacement | ||
| Q3 2021 | BENZALKONIUM CHLORIDE | INTRA-ARTICULAR | INJECTION | 0.02 %w/v | MDE Replacement | ||
| Q4 2021 | BENZALKONIUM CHLORIDE | INTRA-ARTICULAR | INJECTION | 0.8 mg | MDE Replacement | ||
| Q3 2021 | BENZALKONIUM CHLORIDE | INTRALESIONAL | INJECTION | 0.02 %w/v | MDE Replacement | ||
| Q4 2021 | BENZALKONIUM CHLORIDE | INTRALESIONAL | INJECTION | 0.8 mg | MDE Replacement | ||
| Q3 2021 | BENZALKONIUM CHLORIDE | INTRAMUSCULAR | INJECTION | 0.02 %w/v | MDE Replacement | ||
| Q4 2021 | BENZALKONIUM CHLORIDE | INTRAMUSCULAR | INJECTION | 0.8 mg | MDE Replacement | ||
| Q3 2021 | BENZALKONIUM CHLORIDE | NASAL | SPRAY, METERED | 0.70 mg/ 1.00 ml | MDE Replacement | ||
| Q4 2021 | BENZALKONIUM CHLORIDE | NASAL | SPRAY, METERED | 0.8 mg | MDE Replacement | ||
| Q3 2021 | BENZOIC ACID | ORAL | SOLUTION | 2.07 mg/ 1.00 ml | MDE Replacement | ||
| Q4 2021 | BENZOIC ACID | ORAL | SOLUTION | 5.72 mg | MDE Replacement | ||
| Q3 2021 | BENZYL ALCOHOL | INTRAVENOUS | INJECTION | 10.30 %w/v | MDE Replacement | ||
| Q4 2021 | BENZYL ALCOHOL | INTRAVENOUS | INJECTION | 1620 mg | MDE Replacement | ||
| Q3 2021 | BENZYL ALCOHOL | TOPICAL | CREAM | 2.70 %w/w | MDE Replacement | ||
| Q4 2021 | BENZYL ALCOHOL | TOPICAL | CREAM | 30 mg | MDE Replacement | ||
| Q3 2021 | BLACK INK | ORAL | TABLET, EXTENDED RELEASE | 1.00 mg | MDE Replacement | ||
| Q4 2021 | BLACK INK | ORAL | TABLET, EXTENDED RELEASE | 3 mg | MDE Replacement | ||
| Q3 2021 | BUTYLATED HYDROXYTOLUENE | TOPICAL | GEL, METERED | 0.10 %w/w | MDE Replacement | ||
| Q4 2021 | BUTYLATED HYDROXYTOLUENE | TOPICAL | GEL, METERED | 3.5 mg | MDE Replacement | ||
| Q3 2021 | BUTYLPARABEN | ORAL | SUSPENSION | 8.00 mg/ 5.00 ml | MDE Replacement | ||
| Q4 2021 | BUTYLPARABEN | ORAL | SUSPENSION | 12 mg | MDE Replacement | ||
| Q3 2021 | CARBOMER COPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED) | TOPICAL | GEL, METERED | 0.90 %w/w | MDE Replacement | ||
| Q4 2021 | CARBOMER COPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED) | TOPICAL | GEL, METERED | 31.5 mg | MDE Replacement | ||
| Q3 2021 | CARBOMER HOMOPOLYMER TYPE A (ALLYL PENTAERYTHRITOL CROSSLINKED) | TOPICAL | GEL | 0.85 %w/w | MDE Replacement | ||
| Q4 2021 | CARBOMER HOMOPOLYMER TYPE A (ALLYL PENTAERYTHRITOL CROSSLINKED) | TOPICAL | GEL | 8.4 mg | MDE Replacement | ||
| Q3 2021 | CARBOMER HOMOPOLYMER TYPE B (ALLYL PENTAERYTHRITOL CROSSLINKED) | ORAL | CAPSULE | 20.00 mg | MDE Replacement | ||
| Q4 2021 | CARBOMER HOMOPOLYMER TYPE B (ALLYL PENTAERYTHRITOL CROSSLINKED) | ORAL | CAPSULE | 40 mg | MDE Replacement | ||
| Q3 2021 | CARBOMER HOMOPOLYMER TYPE B (ALLYL PENTAERYTHRITOL CROSSLINKED) | ORAL | GRANULE, FOR SUSPENSION | 150.00 mg/ 5.00 ml | MDE Replacement | ||
| Q4 2021 | CARBOMER HOMOPOLYMER TYPE B (ALLYL PENTAERYTHRITOL CROSSLINKED) | ORAL | GRANULE, FOR SUSPENSION | 600 mg | MDE Replacement | ||
| Q3 2021 | CARBOMER HOMOPOLYMER TYPE B (ALLYL SUCROSE CROSSLINKED) | ORAL | SUSPENSION | 50.00 mg/ 5.00 ml | MDE Replacement | ||
| Q4 2021 | CARBOMER HOMOPOLYMER TYPE B (ALLYL SUCROSE CROSSLINKED) | ORAL | SUSPENSION | 288 mg | MDE Replacement | ||
| Q3 2021 | CARBOMER HOMOPOLYMER TYPE B (ALLYL SUCROSE CROSSLINKED) | ORAL | TABLET, EXTENDED RELEASE | 90.00 mg | MDE Replacement | ||
| Q4 2021 | CARBOMER HOMOPOLYMER TYPE B (ALLYL SUCROSE CROSSLINKED) | ORAL | TABLET, EXTENDED RELEASE | 90 mg | MDE Replacement | ||
| Q3 2021 | CARBOMER HOMOPOLYMER TYPE B (ALLYL SUCROSE CROSSLINKED) | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 3.00 mg | MDE Replacement | ||
| Q4 2021 | CARBOMER HOMOPOLYMER TYPE B (ALLYL SUCROSE CROSSLINKED) | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 9 mg | MDE Replacement | ||
| Q3 2021 | CARBOMER HOMOPOLYMER TYPE B (ALLYL SUCROSE CROSSLINKED) | ORAL | TABLET, ORALLY DISINTEGRATING | 0.30 mg | MDE Replacement | ||
| Q4 2021 | CARBOMER HOMOPOLYMER TYPE B (ALLYL SUCROSE CROSSLINKED) | ORAL | TABLET, ORALLY DISINTEGRATING | 1.2 mg | MDE Replacement | ||
| Q3 2021 | CARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED) | TOPICAL | CREAM, AUGMENTED | 1.00 %w/w | MDE Replacement | ||
| Q4 2021 | CARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED) | TOPICAL | CREAM, AUGMENTED | 20 mg | MDE Replacement | ||
| Q3 2021 | CARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED) | TOPICAL | EMULSION | 0.60 %w/w | MDE Replacement | ||
| Q4 2021 | CARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED) | TOPICAL | EMULSION | 6 mg | MDE Replacement | ||
| Q3 2021 | CARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED) | TOPICAL | LOTION | 0.50 %w/w | MDE Replacement | ||
| Q4 2021 | CARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED) | TOPICAL | LOTION | 20 mg | MDE Replacement | ||
| Q3 2021 | CARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED) | TOPICAL | OINTMENT, AUGMENTED | 2.25 %w/w | MDE Replacement | ||
| Q4 2021 | CARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED) | TOPICAL | OINTMENT, AUGMENTED | 22.5 mg | MDE Replacement | ||
| Q3 2021 | CARBOXYMETHYLCELLULOSE SODIUM | BUCCAL | FILM | 17.64 mg | MDE Replacement | ||
| Q4 2021 | CARBOXYMETHYLCELLULOSE SODIUM | BUCCAL | FILM | 17.64 mg | MDE Replacement | ||
| Q3 2021 | CARBOXYMETHYLCELLULOSE SODIUM | BUCCAL | FILM, SOLUBLE | 10.95 mg | MDE Replacement | ||
| Q4 2021 | CARBOXYMETHYLCELLULOSE SODIUM | BUCCAL | FILM, SOLUBLE | 44 mg | MDE Replacement | ||
| Q3 2021 | CARBOXYMETHYLCELLULOSE SODIUM | ORAL | SOLUTION | 35.00 mg/ 1.00 ml | MDE Replacement | ||
| Q4 2021 | CARBOXYMETHYLCELLULOSE SODIUM | ORAL | SOLUTION | 1080 mg | MDE Replacement | ||
| Q3 2021 | CASTOR OIL | ORAL | CAPSULE, EXTENDED RELEASE | 1.76 mg | MDE Replacement | ||
| Q4 2021 | CASTOR OIL | ORAL | CAPSULE, EXTENDED RELEASE | 22 mg | MDE Replacement | ||
| Q3 2021 | CASTOR OIL | ORAL | TABLET | 2.00 mg | MDE Replacement | ||
| Q4 2021 | CASTOR OIL | ORAL | TABLET | 16.8175 mg | MDE Replacement | ||
| Q3 2021 | CELLULOSE MICROCRYSTALLINE/CARBOXYMETHYLCELLULOSE SODIUM | NASAL | SPRAY, METERED | 20.00 mg | MDE Replacement | ||
| Q4 2021 | CELLULOSE MICROCRYSTALLINE/CARBOXYMETHYLCELLULOSE SODIUM | NASAL | SPRAY, METERED | 60 mg | MDE Replacement | ||
| Q3 2021 | CERESIN | VAGINAL | CREAM | 7.00 %w/w | MDE Replacement | ||
| Q4 2021 | CERESIN | VAGINAL | CREAM | 280 mg | MDE Replacement | ||
| Q3 2021 | CROSCARMELLOSE SODIUM | ORAL | TABLET, FILM COATED | 165.00 mg | MDE Replacement | ||
| Q4 2021 | CROSCARMELLOSE SODIUM | ORAL | TABLET, FILM COATED | 330 mg | MDE Replacement | ||
| Q3 2021 | CROSCARMELLOSE SODIUM | ORAL | TABLET, FOR SUSPENSION | 30.00 mg | MDE Replacement | ||
| Q4 2021 | CROSCARMELLOSE SODIUM | ORAL | TABLET, FOR SUSPENSION | 46.4 mg | MDE Replacement | ||
| Q3 2021 | CROSPOVIDONE | ORAL | TABLET, CHEWABLE, EXTENDED RELEASE | 60.00 mg | MDE Replacement | ||
| Q4 2021 | CROSPOVIDONE | ORAL | TABLET, CHEWABLE, EXTENDED RELEASE | 90 mg | MDE Replacement | ||
| Q3 2021 | D&C RED NO. 27 ALUMINUM LAKE | ORAL | TABLET | 0.69 mg | MDE Replacement | ||
| Q4 2021 | D&C RED NO. 27 ALUMINUM LAKE | ORAL | TABLET | 1.2 mg | MDE Replacement | ||
| Q3 2021 | D&C RED NO. 30 | ORAL | TABLET, CHEWABLE, EXTENDED RELEASE | 0.30 mg | MDE Replacement | ||
| Q4 2021 | D&C RED NO. 30 | ORAL | TABLET, CHEWABLE, EXTENDED RELEASE | 0.6 mg | MDE Replacement | ||
| Q3 2021 | D&C RED NO. 30 ALUMINUM LAKE | ORAL | TABLET, COATED | 0.34 mg | MDE Replacement | ||
| Q4 2021 | D&C RED NO. 30 ALUMINUM LAKE | ORAL | TABLET, COATED | 4.96 mg | MDE Replacement | ||
| Q3 2021 | D&C YELLOW NO. 10 ALUMINUM LAKE | BUCCAL | GUM, CHEWING | 2.40 mg | MDE Replacement | ||
| Q4 2021 | D&C YELLOW NO. 10 ALUMINUM LAKE | BUCCAL | GUM, CHEWING | 40.4 mg | MDE Replacement | ||
| Q3 2021 | D&C YELLOW NO. 10 ALUMINUM LAKE | ORAL | TABLET, EXTENDED RELEASE | 2.82 mg | MDE Replacement | ||
| Q4 2021 | D&C YELLOW NO. 10 ALUMINUM LAKE | ORAL | TABLET, EXTENDED RELEASE | 4 mg | MDE Replacement | ||
| Q3 2021 | DIBASIC CALCIUM PHOSPHATE DIHYDRATE | ORAL | TABLET, FILM COATED | 635.50 mg | MDE Replacement | ||
| Q4 2021 | DIBASIC CALCIUM PHOSPHATE DIHYDRATE | ORAL | TABLET, FILM COATED | 953.28 mg | MDE Replacement | ||
| Q3 2021 | DIBUTYL SEBACATE | ORAL | CAPSULE | 15.47 mg | MDE Replacement | ||
| Q4 2021 | DIBUTYL SEBACATE | ORAL | CAPSULE | 30.94 mg | MDE Replacement | ||
| Q3 2021 | DIBUTYL SEBACATE | ORAL | TABLET | 6.00 mg | MDE Replacement | ||
| Q4 2021 | DIBUTYL SEBACATE | ORAL | TABLET | 22.75 mg | MDE Replacement | ||
| Q3 2021 | DIETHYL PHTHALATE | ORAL | CAPSULE | 9.57 mg | MDE Replacement | ||
| Q4 2021 | DIETHYL PHTHALATE | ORAL | CAPSULE | 19.14 mg | MDE Replacement | ||
| Q3 2021 | DIMETHICONE 350 | TOPICAL | CREAM | 1.00 %w/w | MDE Replacement | ||
| Q4 2021 | DIMETHICONE 350 | TOPICAL | CREAM | 114 mg | MDE Replacement | ||
| Q3 2021 | DYE BROWN LAKE BLEND | BUCCAL | GUM, CHEWING | 0.17 mg | MDE Replacement | ||
| Q4 2021 | DYE BROWN LAKE BLEND | BUCCAL | GUM, CHEWING | 3.4 mg | MDE Replacement | ||
| Q3 2021 | EDETATE DISODIUM | INTRACARDIAC | INJECTION | 0.02 %w/v | MDE Replacement | ||
| Q4 2021 | EDETATE DISODIUM | INTRACARDIAC | INJECTION | 1.8 mg | MDE Replacement | ||
| Q3 2021 | EDETATE DISODIUM | TOPICAL | GEL | 0.17 %w/w | MDE Replacement | ||
| Q4 2021 | EDETATE DISODIUM | TOPICAL | GEL | 1 mg | MDE Replacement | ||
| Q3 2021 | EDETATE DISODIUM | VAGINAL | CREAM | 0.05 %w/w | MDE Replacement | ||
| Q4 2021 | EDETATE DISODIUM | VAGINAL | CREAM | 2 mg | MDE Replacement | ||
| Q3 2021 | EGG PHOSPHOLIPIDS | INTRAVENOUS | INJECTION, EMULSION | 14.46 %w/v | MDE Replacement | ||
| Q4 2021 | EGG PHOSPHOLIPIDS | INTRAVENOUS | INJECTION, EMULSION | 2610 mg | MDE Replacement | ||
| Q3 2021 | ETHYLCELLULOSE (10 MPA.S) | ORAL | CAPSULE, DELAYED RELEASE | 11.79 mg | MDE Replacement | ||
| Q4 2021 | ETHYLCELLULOSE (10 MPA.S) | ORAL | CAPSULE, DELAYED RELEASE | 11.79 mg | MDE Replacement | ||
| Q3 2021 | ETHYLCELLULOSE (10 MPA.S) | ORAL | CAPSULE, EXTENDED RELEASE | 175.40 mg | MDE Replacement | ||
| Q4 2021 | ETHYLCELLULOSE (10 MPA.S) | ORAL | CAPSULE, EXTENDED RELEASE | 270 mg | MDE Replacement | ||
| Q3 2021 | ETHYLCELLULOSE (50 MPA.S) | ORAL | CAPSULE | 69.97 mg | MDE Replacement | ||
| Q4 2021 | ETHYLCELLULOSE (50 MPA.S) | ORAL | CAPSULE | 139.94 mg | MDE Replacement | ||
| Q3 2021 | FD&C BLUE NO. 1 ALUMINUM LAKE | ORAL | TABLET | 2.00 mg | MDE Replacement | ||
| Q4 2021 | FD&C BLUE NO. 1 ALUMINUM LAKE | ORAL | TABLET | 6 mg | MDE Replacement | ||
| Q3 2021 | FD&C RED NO. 30--ALUMINUM LAKE | ORAL | TABLET | 0.40 mg | MDE Replacement | ||
| Q4 2021 | FD&C RED NO. 30--ALUMINUM LAKE | ORAL | TABLET | 1.92 mg | MDE Replacement | ||
| Q3 2021 | FERRIC OXIDE BROWN | ORAL | CAPSULE | 1.12 mg | MDE Replacement | ||
| Q4 2021 | FERRIC OXIDE BROWN | ORAL | CAPSULE | 7.84 mg | MDE Replacement | ||
| Q3 2021 | FERRIC OXIDE RED | ORAL | TABLET, FILM COATED | 3.00 mg | MDE Replacement | ||
| Q4 2021 | FERRIC OXIDE RED | ORAL | TABLET, FILM COATED | 3.07 mg | MDE Replacement | ||
| Q3 2021 | FERRIC OXIDE YELLOW | ORAL | CAPSULE, EXTENDED RELEASE | 3.04 mg | MDE Replacement | ||
| Q4 2021 | FERRIC OXIDE YELLOW | ORAL | CAPSULE, EXTENDED RELEASE | 6.84 mg | MDE Replacement | ||
| Q3 2021 | FERRIC OXIDE YELLOW | ORAL | GRANULE, FOR SUSPENSION | 1.80 mg | MDE Replacement | ||
| Q4 2021 | FERRIC OXIDE YELLOW | ORAL | GRANULE, FOR SUSPENSION | 10.8 mg | MDE Replacement | ||
| Q3 2021 | FLAVOR BANANA FN-6713 | ORAL | SOLUTION | 20.00 mg/ 5.00 ml | MDE Replacement | ||
| Q4 2021 | FLAVOR BANANA FN-6713 | ORAL | SOLUTION | 117.12 mg | MDE Replacement | ||
| Q3 2021 | FLAVOR BANANA GIVAUDAN 85509 | ORAL | SOLUTION | 1.03 mg/ 1.00 ml | MDE Replacement | ||
| Q4 2021 | FLAVOR BANANA GIVAUDAN 85509 | ORAL | SOLUTION | 30.93 mg | MDE Replacement | ||
| Q3 2021 | FLAVOR CITRUS/FRUIT FREEZE 1100609500 | BUCCAL | GUM, CHEWING | 2.25 mg | MDE Replacement | ||
| Q4 2021 | FLAVOR CITRUS/FRUIT FREEZE 1100609500 | BUCCAL | GUM, CHEWING | 45 mg | MDE Replacement | ||
| Q3 2021 | FLAVOR FRUIT FN-6714 | ORAL | SOLUTION | 2.50 mg/ 5.00 ml | MDE Replacement | ||
| Q4 2021 | FLAVOR FRUIT FN-6714 | ORAL | SOLUTION | 36 mg | MDE Replacement | ||
| Q3 2021 | FLAVOR GRAPE PFC-9924 | ORAL | SOLUTION | 4.10 mg/ 1.00 ml | MDE Replacement | ||
| Q4 2021 | FLAVOR GRAPE PFC-9924 | ORAL | SOLUTION | 15 mg | MDE Replacement | ||
| Q3 2021 | FLAVOR MENTHOL VERALOCK | BUCCAL | GUM, CHEWING | 3.84 mg | MDE Replacement | ||
| Q4 2021 | FLAVOR MENTHOL VERALOCK | BUCCAL | GUM, CHEWING | 76.8 mg | MDE Replacement | ||
| Q3 2021 | FLAVOR MINT 287 | BUCCAL | GUM, CHEWING | 28.00 mg | MDE Replacement | ||
| Q4 2021 | FLAVOR MINT 287 | BUCCAL | GUM, CHEWING | 560 mg | MDE Replacement | ||
| Q3 2021 | FLAVOR PEPPERMINT EXTRACT FN-2356 | ORAL | SOLUTION | 5.00 mg/ 1.00 ml | MDE Replacement | ||
| Q4 2021 | FLAVOR PEPPERMINT EXTRACT FN-2356 | ORAL | SOLUTION | 288 mg | MDE Replacement | ||
| Q3 2021 | GLYCERIN | ORAL | SUSPENSION | 23520.00 mg | MDE Replacement | ||
| Q4 2021 | GLYCERIN | ORAL | SUSPENSION | 26208 mg | MDE Replacement | ||
| Q3 2021 | GLYCERYL DIBEHENATE | ORAL | POWDER, FOR SOLUTION | 2.00 mg | MDE Replacement | ||
| Q4 2021 | GLYCERYL DIBEHENATE | ORAL | POWDER, FOR SOLUTION | 2 mg | MDE Replacement | ||
| Q3 2021 | GLYCERYL MONO AND DIPALMITOSTEARATE | VAGINAL | CREAM | 4.00 %w/w | MDE Replacement | ||
| Q4 2021 | GLYCERYL MONO AND DIPALMITOSTEARATE | VAGINAL | CREAM | 160 mg | MDE Replacement | ||
| Q3 2021 | GLYCERYL MONOCAPRYLOCAPRATE | ORAL | CAPSULE | 374.24 mg | MDE Replacement | ||
| Q4 2021 | GLYCERYL MONOCAPRYLOCAPRATE | ORAL | CAPSULE | 501.9 mg | MDE Replacement | ||
| Q3 2021 | GUAR GUM | ORAL | TABLET, CHEWABLE, EXTENDED RELEASE | 24.00 mg | MDE Replacement | ||
| Q4 2021 | GUAR GUM | ORAL | TABLET, CHEWABLE, EXTENDED RELEASE | 36 mg | MDE Replacement | ||
| Q3 2021 | HYDROGENATED COTTONSEED OIL | ORAL | TABLET | 34.00 mg | MDE Replacement | ||
| Q4 2021 | HYDROGENATED COTTONSEED OIL | ORAL | TABLET | 54.4 mg | MDE Replacement | ||
| Q3 2021 | HYDROGENATED COTTONSEED OIL | ORAL | TABLET, EXTENDED RELEASE | 228.00 mg | MDE Replacement | ||
| Q4 2021 | HYDROGENATED COTTONSEED OIL | ORAL | TABLET, EXTENDED RELEASE | 2280 mg | MDE Replacement | ||
| Q3 2021 | HYDROGENATED SOYBEAN OIL | ORAL | TABLET, EXTENDED RELEASE | 48.00 mg | MDE Replacement | ||
| Q4 2021 | HYDROGENATED SOYBEAN OIL | ORAL | TABLET, EXTENDED RELEASE | 96 mg | MDE Replacement | ||
| Q3 2021 | HYDROXYETHYL CELLULOSE (140 MPA.S AT 5%) | BUCCAL | FILM | 54.92 mg | MDE Replacement | ||
| Q4 2021 | HYDROXYETHYL CELLULOSE (140 MPA.S AT 5%) | BUCCAL | FILM | 54.92 mg | MDE Replacement | ||
| Q3 2021 | HYDROXYETHYL CELLULOSE (140 MPA.S AT 5%) | BUCCAL | FILM, SOLUBLE | 39.88 mg | MDE Replacement | ||
| Q4 2021 | HYDROXYETHYL CELLULOSE (140 MPA.S AT 5%) | BUCCAL | FILM, SOLUBLE | 160 mg | MDE Replacement | ||
| Q3 2021 | HYDROXYETHYL CELLULOSE (4000 MPA.S AT 1%) | ORAL | TABLET, EXTENDED RELEASE | 400.00 mg | MDE Replacement | ||
| Q4 2021 | HYDROXYETHYL CELLULOSE (4000 MPA.S AT 1%) | ORAL | TABLET, EXTENDED RELEASE | 800 mg | MDE Replacement | ||
| Q3 2021 | HYDROXYETHYL CELLULOSE (4000 MPA.S AT 1%) | TOPICAL | GEL | 1.50 %w/w | MDE Replacement | ||
| Q4 2021 | HYDROXYETHYL CELLULOSE (4000 MPA.S AT 1%) | TOPICAL | GEL | 25 mg | MDE Replacement | ||
| Q3 2021 | HYDROXYETHYL CELLULOSE (6500 MPA.S AT 2%) | ORAL | TABLET, EXTENDED RELEASE | 150.00 mg | MDE Replacement | ||
| Q4 2021 | HYDROXYETHYL CELLULOSE (6500 MPA.S AT 2%) | ORAL | TABLET, EXTENDED RELEASE | 300 mg | MDE Replacement | ||
| Q3 2021 | HYDROXYPROPYL CELLULOSE (1600000 WAMW) | BUCCAL | FILM, SOLUBLE | 72.91 mg | MDE Replacement | ||
| Q4 2021 | HYDROXYPROPYL CELLULOSE (1600000 WAMW) | BUCCAL | FILM, SOLUBLE | 292 mg | MDE Replacement | ||
| Q3 2021 | HYDROXYPROPYL CELLULOSE (1600000 WAMW) | ORAL | GRANULE, FOR SUSPENSION | 39.00 mg | MDE Replacement | ||
| Q4 2021 | HYDROXYPROPYL CELLULOSE (1600000 WAMW) | ORAL | GRANULE, FOR SUSPENSION | 193.8 mg | MDE Replacement | ||
| Q3 2021 | HYPROMELLOSE | ORAL | CAPSULE, DELAYED RELEASE | 4.50 mg | MDE Replacement | ||
| Q4 2021 | HYPROMELLOSE | ORAL | CAPSULE, DELAYED RELEASE | 34.85 mg | MDE Replacement | ||
| Q3 2021 | HYPROMELLOSE | ORAL | TABLET, COATED | 35.39 mg | MDE Replacement | ||
| Q4 2021 | HYPROMELLOSE | ORAL | TABLET, COATED | 57.6 mg | MDE Replacement | ||
| Q3 2021 | HYPROMELLOSE 2208 (100 MPA.S) | ORAL | SUSPENSION | 50.00 mg/ 5.00 ml | MDE Replacement | ||
| Q4 2021 | HYPROMELLOSE 2208 (100 MPA.S) | ORAL | SUSPENSION | 50 mg | MDE Replacement | ||
| Q3 2021 | HYPROMELLOSE 2208 (100 MPA.S) | ORAL | SYRUP | 12.50 mg/ 5.00 ml | MDE Replacement | ||
| Q4 2021 | HYPROMELLOSE 2208 (100 MPA.S) | ORAL | SYRUP | 100 mg | MDE Replacement | ||
| Q3 2021 | HYPROMELLOSE 2208 (100 MPA.S) | ORAL | TABLET, DELAYED RELEASE | 90.00 mg | MDE Replacement | ||
| Q4 2021 | HYPROMELLOSE 2208 (100 MPA.S) | ORAL | TABLET, DELAYED RELEASE | 360 mg | MDE Replacement | ||
| Q3 2021 | HYPROMELLOSE 2208 (15000 MPA.S) | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 300.00 mg | MDE Replacement | ||
| Q4 2021 | HYPROMELLOSE 2208 (15000 MPA.S) | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 400 mg | MDE Replacement | ||
| Q3 2021 | HYPROMELLOSE 2208 (200000 MPA.S) | ORAL | TABLET, EXTENDED RELEASE | 212.00 mg | MDE Replacement | ||
| Q4 2021 | HYPROMELLOSE 2208 (200000 MPA.S) | ORAL | TABLET, EXTENDED RELEASE | 460 mg | MDE Replacement | ||
| Q3 2021 | HYPROMELLOSE 2208 (4000 MPA.S) | VAGINAL | CREAM | 0.30 %w/w | MDE Replacement | ||
| Q4 2021 | HYPROMELLOSE 2208 (4000 MPA.S) | VAGINAL | CREAM | 12 mg | MDE Replacement | ||
| Q3 2021 | HYPROMELLOSE 2910 (15 MPA.S) | ORAL | CAPSULE, EXTENDED RELEASE | 54.40 mg | MDE Replacement | ||
| Q4 2021 | HYPROMELLOSE 2910 (15 MPA.S) | ORAL | CAPSULE, EXTENDED RELEASE | 70.7 mg | MDE Replacement | ||
| Q3 2021 | HYPROMELLOSE 2910 (15 MPA.S) | ORAL | TABLET, EXTENDED RELEASE | 255.85 mg | MDE Replacement | ||
| Q4 2021 | HYPROMELLOSE 2910 (15 MPA.S) | ORAL | TABLET, EXTENDED RELEASE | 510 mg | MDE Replacement | ||
| Q3 2021 | HYPROMELLOSE 2910 (15 MPA.S) | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 7.50 mg | MDE Replacement | ||
| Q4 2021 | HYPROMELLOSE 2910 (15 MPA.S) | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 15 mg | MDE Replacement | ||
| Q3 2021 | HYPROMELLOSE 2910 (3 MPA.S) | ORAL | CAPSULE | 193.91 mg | MDE Replacement | ||
| Q4 2021 | HYPROMELLOSE 2910 (3 MPA.S) | ORAL | CAPSULE | 775.64 mg | MDE Replacement | ||
| Q3 2021 | HYPROMELLOSE 2910 (3 MPA.S) | ORAL | GRANULE | 10.40 mg | MDE Replacement | ||
| Q4 2021 | HYPROMELLOSE 2910 (3 MPA.S) | ORAL | GRANULE | 21 mg | MDE Replacement | ||
| Q3 2021 | HYPROMELLOSE 2910 (3 MPA.S) | ORAL | GRANULE, FOR SUSPENSION | 1.00 mg | MDE Replacement | ||
| Q4 2021 | HYPROMELLOSE 2910 (3 MPA.S) | ORAL | GRANULE, FOR SUSPENSION | 1 mg | MDE Replacement | ||
| Q3 2021 | HYPROMELLOSE 2910 (3 MPA.S) | ORAL | TABLET, EXTENDED RELEASE | 42.41 mg | MDE Replacement | ||
| Q4 2021 | HYPROMELLOSE 2910 (3 MPA.S) | ORAL | TABLET, EXTENDED RELEASE | 53.32 mg | MDE Replacement | ||
| Q3 2021 | HYPROMELLOSE 2910 (4000 MPA.S) | NASAL | SPRAY, METERED | 1.00 mg/ 1.00 ml | MDE Replacement | ||
| Q4 2021 | HYPROMELLOSE 2910 (4000 MPA.S) | NASAL | SPRAY, METERED | 1.096 mg | MDE Replacement | ||
| Q3 2021 | HYPROMELLOSE 2910 (4000 MPA.S) | ORAL | SYRUP | 180.00 mg/ 5.00 ml | MDE Replacement | ||
| Q4 2021 | HYPROMELLOSE 2910 (4000 MPA.S) | ORAL | SYRUP | 360 mg | MDE Replacement | ||
| Q3 2021 | HYPROMELLOSE 2910 (5 MPA.S) | ORAL | CAPSULE, EXTENDED RELEASE | 670.04 mg | MDE Replacement | ||
| Q4 2021 | HYPROMELLOSE 2910 (5 MPA.S) | ORAL | CAPSULE, EXTENDED RELEASE | 963.81 mg | MDE Replacement | ||
| Q3 2021 | HYPROMELLOSE 2910 (5 MPA.S) | ORAL | GRANULE, FOR SUSPENSION | 24.08 mg | MDE Replacement | ||
| Q4 2021 | HYPROMELLOSE 2910 (5 MPA.S) | ORAL | GRANULE, FOR SUSPENSION | 48.16 mg | MDE Replacement | ||
| Q3 2021 | HYPROMELLOSE 2910 (5 MPA.S) | ORAL | POWDER, FOR SUSPENSION | 75.00 mg/ 5.00 ml | MDE Replacement | ||
| Q4 2021 | HYPROMELLOSE 2910 (5 MPA.S) | ORAL | POWDER, FOR SUSPENSION | 450 mg | MDE Replacement | ||
| Q3 2021 | HYPROMELLOSE 2910 (5 MPA.S) | ORAL | SUSPENSION | 325.00 mg/ 5.00 ml | MDE Replacement | ||
| Q4 2021 | HYPROMELLOSE 2910 (5 MPA.S) | ORAL | SUSPENSION | 975 mg | MDE Replacement | ||
| Q3 2021 | HYPROMELLOSE 2910 (5 MPA.S) | ORAL | SYRUP | 5.00 mg/ 1.00 ml | MDE Replacement | ||
| Q4 2021 | HYPROMELLOSE 2910 (5 MPA.S) | ORAL | SYRUP | 200 mg | MDE Replacement | ||
| Q3 2021 | HYPROMELLOSE 2910 (5 MPA.S) | ORAL | TABLET | 444.40 mg | MDE Replacement | ||
| Q4 2021 | HYPROMELLOSE 2910 (5 MPA.S) | ORAL | TABLET | 1200 mg | MDE Replacement | ||
| Q3 2021 | HYPROMELLOSE 2910 (5 MPA.S) | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 54.00 mg | MDE Replacement | ||
| Q4 2021 | HYPROMELLOSE 2910 (5 MPA.S) | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 106.6 mg | MDE Replacement | ||
| Q3 2021 | HYPROMELLOSE 2910 (5 MPA.S) | ORAL | TABLET, FOR SUSPENSION | 19.00 mg | MDE Replacement | ||
| Q4 2021 | HYPROMELLOSE 2910 (5 MPA.S) | ORAL | TABLET, FOR SUSPENSION | 76 mg | MDE Replacement | ||
| Q3 2021 | HYPROMELLOSE 2910 (6 MPA.S) | ORAL | CAPSULE, DELAYED RELEASE | 78.00 mg | MDE Replacement | ||
| Q4 2021 | HYPROMELLOSE 2910 (6 MPA.S) | ORAL | CAPSULE, DELAYED RELEASE | 223 mg | MDE Replacement | ||
| Q3 2021 | HYPROMELLOSE ACETATE SUCCINATE | ORAL | CAPSULE, EXTENDED RELEASE | 66.78 mg | MDE Replacement | ||
| Q4 2021 | HYPROMELLOSE ACETATE SUCCINATE | ORAL | CAPSULE, EXTENDED RELEASE | 66.78 mg | MDE Replacement | ||
| Q3 2021 | INK BLACK SW-9008 | ORAL | CAPSULE, EXTENDED RELEASE | 0.28 mg | MDE Replacement | ||
| Q4 2021 | INK BLACK SW-9008 | ORAL | CAPSULE, EXTENDED RELEASE | 0.675 mg | MDE Replacement | ||
| Q3 2021 | ISOMALT | SUBLINGUAL | POWDER | 176.80 mg | MDE Replacement | ||
| Q4 2021 | ISOMALT | SUBLINGUAL | POWDER | 530.4 mg | MDE Replacement | ||
| Q3 2021 | ISOPROPYL PALMITATE | TOPICAL | CREAM | 5.00 %w/w | MDE Replacement | ||
| Q4 2021 | ISOPROPYL PALMITATE | TOPICAL | CREAM | 32.15 mg | MDE Replacement | ||
| Q3 2021 | LACTOSE MONOHYDRATE | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 260.00 mg | MDE Replacement | ||
| Q4 2021 | LACTOSE MONOHYDRATE | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 520 mg | MDE Replacement | ||
| Q3 2021 | LIGHT MINERAL OIL | TOPICAL | CREAM | 20.00 %w/w | MDE Replacement | ||
| Q4 2021 | LIGHT MINERAL OIL | TOPICAL | CREAM | 456 mg | MDE Replacement | ||
| Q3 2021 | LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE (11% HYDROXYPROPYL; 120000 MW) | ORAL | TABLET | 80.00 mg | MDE Replacement | ||
| Q4 2021 | LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE (11% HYDROXYPROPYL; 120000 MW) | ORAL | TABLET | 369.6 mg | MDE Replacement | ||
| Q3 2021 | LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE (11% HYDROXYPROPYL; 120000 MW) | ORAL | TABLET, DELAYED RELEASE | 26.30 mg | MDE Replacement | ||
| Q4 2021 | LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE (11% HYDROXYPROPYL; 120000 MW) | ORAL | TABLET, DELAYED RELEASE | 84 mg | MDE Replacement | ||
| Q3 2021 | MAGNESIUM OXIDE | BUCCAL | GUM, CHEWING | 7.20 mg | MDE Replacement | ||
| Q4 2021 | MAGNESIUM OXIDE | BUCCAL | GUM, CHEWING | 144 mg | MDE Replacement | ||
| Q3 2021 | MAGNESIUM STEARATE | ORAL | TABLET, CHEWABLE, EXTENDED RELEASE | 6.00 mg | MDE Replacement | ||
| Q4 2021 | MAGNESIUM STEARATE | ORAL | TABLET, CHEWABLE, EXTENDED RELEASE | 9 mg | MDE Replacement | ||
| Q3 2021 | MAGNESIUM STEARATE | ORAL | TABLET, EXTENDED RELEASE | 150.00 mg | MDE Replacement | ||
| Q4 2021 | MAGNESIUM STEARATE | ORAL | TABLET, EXTENDED RELEASE | 160 mg | MDE Replacement | ||
| Q3 2021 | MALTODEXTRIN | ORAL | SOLUTION | 145.10 mg | MDE Replacement | ||
| Q4 2021 | MALTODEXTRIN | ORAL | SOLUTION | 1451 mg | MDE Replacement | ||
| Q3 2021 | MANNITOL | INTRAVENOUS | INJECTION | 1000.00 mg | MDE Replacement | ||
| Q4 2021 | MANNITOL | INTRAVENOUS | INJECTION | 15200 mg | MDE Replacement | ||
| Q3 2021 | MANNITOL | ORAL | CAPSULE, EXTENDED RELEASE | 53.40 mg | MDE Replacement | ||
| Q4 2021 | MANNITOL | ORAL | CAPSULE, EXTENDED RELEASE | 160.2 mg | MDE Replacement | ||
| Q3 2021 | MANNITOL | ORAL | POWDER, FOR SOLUTION | 1345.50 mg | MDE Replacement | ||
| Q4 2021 | MANNITOL | ORAL | POWDER, FOR SOLUTION | 3767.4 mg | MDE Replacement | ||
| Q3 2021 | MANNITOL | ORAL | TABLET, CHEWABLE, EXTENDED RELEASE | 410.60 mg | MDE Replacement | ||
| Q4 2021 | MANNITOL | ORAL | TABLET, CHEWABLE, EXTENDED RELEASE | 615.9 mg | MDE Replacement | ||
| Q3 2021 | MANNITOL | ORAL | TABLET, EXTENDED RELEASE | 392.20 mg | MDE Replacement | ||
| Q4 2021 | MANNITOL | ORAL | TABLET, EXTENDED RELEASE | 434 mg | MDE Replacement | ||
| Q3 2021 | MEDIUM-CHAIN TRIGLYCERIDES | SUBLINGUAL | POWDER | 0.80 mg | MDE Replacement | ||
| Q4 2021 | MEDIUM-CHAIN TRIGLYCERIDES | SUBLINGUAL | POWDER | 2.4 mg | MDE Replacement | ||
| Q3 2021 | MEDIUM-CHAIN TRIGLYCERIDES | TOPICAL | CREAM | 15.00 %w/w | MDE Replacement | ||
| Q4 2021 | MEDIUM-CHAIN TRIGLYCERIDES | TOPICAL | CREAM | 570 mg | MDE Replacement | ||
| Q3 2021 | METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | ORAL | GRANULE, FOR SUSPENSION | 38.00 mg | MDE Replacement | ||
| Q4 2021 | METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A | ORAL | GRANULE, FOR SUSPENSION | 82.2 mg | MDE Replacement | ||
| Q3 2021 | METHACRYLIC ACID COPOLYMER | ORAL | TABLET, EXTENDED RELEASE | 61.91 mg | MDE Replacement | ||
| Q4 2021 | METHACRYLIC ACID COPOLYMER | ORAL | TABLET, EXTENDED RELEASE | 99.3 mg | MDE Replacement | ||
| Q3 2021 | METHYLCELLULOSE | ORAL | TABLET | 183.60 mg | MDE Replacement | ||
| Q4 2021 | METHYLCELLULOSE | ORAL | TABLET | 816 mg | MDE Replacement | ||
| Q3 2021 | METHYLCELLULOSE (1500 MPA.S) | ORAL | TABLET | 2.75 mg | MDE Replacement | ||
| Q4 2021 | METHYLCELLULOSE (1500 MPA.S) | ORAL | TABLET | 319.2 mg | MDE Replacement | ||
| Q3 2021 | METHYLPARABEN | BUCCAL | FILM | 1.00 mg | MDE Replacement | ||
| Q4 2021 | METHYLPARABEN | BUCCAL | FILM | 1 mg | MDE Replacement | ||
| Q3 2021 | METHYLPARABEN | BUCCAL | FILM, SOLUBLE | 0.71 mg | MDE Replacement | ||
| Q4 2021 | METHYLPARABEN | BUCCAL | FILM, SOLUBLE | 3 mg | MDE Replacement | ||
| Q3 2021 | METHYLPARABEN | VAGINAL | CREAM | 0.20 %w/w | MDE Replacement | ||
| Q4 2021 | METHYLPARABEN | VAGINAL | CREAM | 6 mg | MDE Replacement | ||
| Q3 2021 | MICROCRYSTALLINE CELLULOSE | ORAL | TABLET, CHEWABLE, EXTENDED RELEASE | 96.00 mg | MDE Replacement | ||
| Q4 2021 | MICROCRYSTALLINE CELLULOSE | ORAL | TABLET, CHEWABLE, EXTENDED RELEASE | 144 mg | MDE Replacement | ||
| Q3 2021 | MINERAL OIL | TOPICAL | CREAM | 50.62 %w/w | MDE Replacement | ||
| Q4 2021 | MINERAL OIL | TOPICAL | CREAM | 1518 mg | MDE Replacement | ||
| Q3 2021 | MONOBASIC POTASSIUM PHOSPHATE | INTRAVENOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 68.00 mg | MDE Replacement | ||
| Q4 2021 | MONOBASIC POTASSIUM PHOSPHATE | INTRAVENOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 110.16 mg | MDE Replacement | ||
| Q3 2021 | N,N-DIMETHYLACETAMIDE | INTRAVENOUS | INJECTION | 30.89 %w/v | MDE Replacement | ||
| Q4 2021 | N,N-DIMETHYLACETAMIDE | INTRAVENOUS | INJECTION | 12320 mg | MDE Replacement | ||
| Q3 2021 | OLEIC ACID | ORAL | TABLET, EXTENDED RELEASE | 2.00 mg | MDE Replacement | ||
| Q4 2021 | OLEIC ACID | ORAL | TABLET, EXTENDED RELEASE | 2.95 mg | MDE Replacement | ||
| Q3 2021 | OLEIC ACID | TOPICAL | GEL, METERED | 2.50 %w/w | MDE Replacement | ||
| Q4 2021 | OLEIC ACID | TOPICAL | GEL, METERED | 87.5 mg | MDE Replacement | ||
| Q3 2021 | OPADRY 03B58902 WHITE | ORAL | TABLET | 10.50 mg | MDE Replacement | ||
| Q4 2021 | OPADRY 03B58902 WHITE | ORAL | TABLET | 21 mg | MDE Replacement | ||
| Q3 2021 | OPADRY 03F14895 PINK | ORAL | TABLET, FILM COATED | 4.00 mg | MDE Replacement | ||
| Q4 2021 | OPADRY 03F14895 PINK | ORAL | TABLET, FILM COATED | 8 mg | MDE Replacement | ||
| Q3 2021 | OPADRY 03F59016 CLEAR | ORAL | TABLET, EXTENDED RELEASE | 4.00 mg | MDE Replacement | ||
| Q4 2021 | OPADRY 03F59016 CLEAR | ORAL | TABLET, EXTENDED RELEASE | 8 mg | MDE Replacement | ||
| Q3 2021 | OPADRY AMB 80W68912 WHITE | ORAL | TABLET, EXTENDED RELEASE | 36.00 mg | MDE Replacement | ||
| Q4 2021 | OPADRY AMB 80W68912 WHITE | ORAL | TABLET, EXTENDED RELEASE | 72 mg | MDE Replacement | ||
| Q3 2021 | OPADRY AMB 80W68912 WHITE | ORAL | TABLET, FILM COATED | 18.00 mg | MDE Replacement | ||
| Q4 2021 | OPADRY AMB 80W68912 WHITE | ORAL | TABLET, FILM COATED | 18 mg | MDE Replacement | ||
| Q3 2021 | OPADRY II 33G28707 WHITE | ORAL | TABLET, EXTENDED RELEASE | 30.00 mg | MDE Replacement | ||
| Q4 2021 | OPADRY II 33G28707 WHITE | ORAL | TABLET, EXTENDED RELEASE | 60 mg | MDE Replacement | ||
| Q3 2021 | OPADRY II 49B10882 BLUE | ORAL | TABLET | 26.90 mg | MDE Replacement | ||
| Q4 2021 | OPADRY II 49B10882 BLUE | ORAL | TABLET | 53.8 mg | MDE Replacement | ||
| Q3 2021 | OPADRY II 85F18422 WHITE | ORAL | TABLET, EXTENDED RELEASE | 51.30 mg | MDE Replacement | ||
| Q4 2021 | OPADRY II 85F18422 WHITE | ORAL | TABLET, EXTENDED RELEASE | 72 mg | MDE Replacement | ||
| Q3 2021 | OPADRY OY-58900 WHITE | ORAL | TABLET | 31.80 mg | MDE Replacement | ||
| Q4 2021 | OPADRY OY-58900 WHITE | ORAL | TABLET | 132 mg | MDE Replacement | ||
| Q3 2021 | OPADRY OY-58900 WHITE | ORAL | TABLET, FILM COATED | 16.25 mg | MDE Replacement | ||
| Q4 2021 | OPADRY OY-58900 WHITE | ORAL | TABLET, FILM COATED | 65 mg | MDE Replacement | ||
| Q3 2021 | OPADRY Y-5-7068 WHITE | ORAL | TABLET | 120.00 mg | MDE Replacement | ||
| Q4 2021 | OPADRY Y-5-7068 WHITE | ORAL | TABLET | 290.25 mg | MDE Replacement | ||
| Q3 2021 | OPADRY YS-1-7003 WHITE | ORAL | TABLET | 147.80 mg | MDE Replacement | ||
| Q4 2021 | OPADRY YS-1-7003 WHITE | ORAL | TABLET | 402.84 mg | MDE Replacement | ||
| Q3 2021 | OPADRY YS-1-7006 CLEAR | ORAL | TABLET | 56.05 mg | MDE Replacement | ||
| Q4 2021 | OPADRY YS-1-7006 CLEAR | ORAL | TABLET | 111.24 mg | MDE Replacement | ||
| Q3 2021 | OPADRY YS-1-7472 CLEAR | ORAL | CAPSULE, EXTENDED RELEASE | 50.76 mg | MDE Replacement | ||
| Q4 2021 | OPADRY YS-1-7472 CLEAR | ORAL | CAPSULE, EXTENDED RELEASE | 50.76 mg | MDE Replacement | ||
| Q3 2021 | OPADRY YS-1R-7006 CLEAR | ORAL | TABLET | 26.25 mg | MDE Replacement | ||
| Q4 2021 | OPADRY YS-1R-7006 CLEAR | ORAL | TABLET | 37.54 mg | MDE Replacement | ||
| Q3 2021 | PEPPERMINT OIL | BUCCAL | FILM, SOLUBLE | 0.85 mg | MDE Replacement | ||
| Q4 2021 | PEPPERMINT OIL | BUCCAL | FILM, SOLUBLE | 3 mg | MDE Replacement | ||
| Q3 2021 | PEPPERMINT OIL | SUBLINGUAL | POWDER | 0.40 mg | MDE Replacement | ||
| Q4 2021 | PEPPERMINT OIL | SUBLINGUAL | POWDER | 1.2 mg | MDE Replacement | ||
| Q3 2021 | PHENOXYETHANOL | TOPICAL | CREAM | 1.00 %w/w | MDE Replacement | ||
| Q4 2021 | PHENOXYETHANOL | TOPICAL | CREAM | 57 mg | MDE Replacement | ||
| Q3 2021 | PHENYLETHYL ALCOHOL | NASAL | SPRAY, METERED | 2.50 mg | MDE Replacement | ||
| Q4 2021 | PHENYLETHYL ALCOHOL | NASAL | SPRAY, METERED | 10 mg | MDE Replacement | ||
| Q3 2021 | PLASACRYL T20 | ORAL | CAPSULE, EXTENDED RELEASE | 3.98 mg | MDE Replacement | ||
| Q4 2021 | PLASACRYL T20 | ORAL | CAPSULE, EXTENDED RELEASE | 3.98 mg | MDE Replacement | ||
| Q3 2021 | POLACRILIN POTASSIUM | ORAL | CAPSULE | 45.28 mg | MDE Replacement | ||
| Q4 2021 | POLACRILIN POTASSIUM | ORAL | CAPSULE | 54.95 mg | MDE Replacement | ||
| Q3 2021 | POLACRILIN POTASSIUM | ORAL | SUSPENSION | 20.00 mg/ 5.00 ml | MDE Replacement | ||
| Q4 2021 | POLACRILIN POTASSIUM | ORAL | SUSPENSION | 120 mg | MDE Replacement | ||
| Q3 2021 | POLOXAMER 407 | ORAL | CAPSULE, DELAYED RELEASE | 5.00 mg | MDE Replacement | ||
| Q4 2021 | POLOXAMER 407 | ORAL | CAPSULE, DELAYED RELEASE | 5 mg | MDE Replacement | ||
| Q3 2021 | POLYCARBOPHIL | BUCCAL | FILM, SOLUBLE | 1.37 mg | MDE Replacement | ||
| Q4 2021 | POLYCARBOPHIL | BUCCAL | FILM, SOLUBLE | 5.48 mg | MDE Replacement | ||
| Q3 2021 | POLYETHYLENE GLYCOL 400 | INTRAVENOUS | INJECTION | 7470.00 mg | MDE Replacement | ||
| Q4 2021 | POLYETHYLENE GLYCOL 400 | INTRAVENOUS | INJECTION | 25013.3 mg | MDE Replacement | ||
| Q3 2021 | POLYETHYLENE GLYCOL 4000 | ORAL | TABLET, FILM COATED | 4.20 mg | MDE Replacement | ||
| Q4 2021 | POLYETHYLENE GLYCOL 4000 | ORAL | TABLET, FILM COATED | 4.5 mg | MDE Replacement | ||
| Q3 2021 | POLYETHYLENE GLYCOL 8000 | ORAL | TABLET, EXTENDED RELEASE | 144.60 mg | MDE Replacement | ||
| Q4 2021 | POLYETHYLENE GLYCOL 8000 | ORAL | TABLET, EXTENDED RELEASE | 242 mg | MDE Replacement | ||
| Q3 2021 | POLYETHYLENE OXIDE 200000 | ORAL | TABLET | 173.99 mg | MDE Replacement | ||
| Q4 2021 | POLYETHYLENE OXIDE 200000 | ORAL | TABLET | 347.98 mg | MDE Replacement | ||
| Q3 2021 | POLYETHYLENE OXIDE 200000 | ORAL | TABLET, EXTENDED RELEASE | 345.00 mg | MDE Replacement | ||
| Q4 2021 | POLYETHYLENE OXIDE 200000 | ORAL | TABLET, EXTENDED RELEASE | 460 mg | MDE Replacement | ||
| Q3 2021 | POLYETHYLENE OXIDE 4000000 | ORAL | TABLET, EXTENDED RELEASE | 188.10 mg | MDE Replacement | ||
| Q4 2021 | POLYETHYLENE OXIDE 4000000 | ORAL | TABLET, EXTENDED RELEASE | 250.8 mg | MDE Replacement | ||
| Q3 2021 | POLYETHYLENE OXIDE 7000000 | ORAL | TABLET | 132.66 mg | MDE Replacement | ||
| Q4 2021 | POLYETHYLENE OXIDE 7000000 | ORAL | TABLET | 265.32 mg | MDE Replacement | ||
| Q3 2021 | POLYISOBUTYLENE (1100000 MW) | TOPICAL | SYSTEM | 66.78 mg | MDE Replacement | ||
| Q4 2021 | POLYISOBUTYLENE (1100000 MW) | TOPICAL | SYSTEM | 66.78 mg | MDE Replacement | ||
| Q3 2021 | POLYSORBATE 80 | ORAL | GRANULE, FOR SUSPENSION | 15.00 mg | MDE Replacement | ||
| Q4 2021 | POLYSORBATE 80 | ORAL | GRANULE, FOR SUSPENSION | 125 mg | MDE Replacement | ||
| Q3 2021 | POLYVINYL ACETATE | ORAL | TABLET, CHEWABLE, EXTENDED RELEASE | 25.82 mg | MDE Replacement | ||
| Q4 2021 | POLYVINYL ACETATE | ORAL | TABLET, CHEWABLE, EXTENDED RELEASE | 38.74 mg | MDE Replacement | ||
| Q3 2021 | POTASSIUM CHLORIDE | ORAL | TABLET, EXTENDED RELEASE | 9.90 mg | MDE Replacement | ||
| Q4 2021 | POTASSIUM CHLORIDE | ORAL | TABLET, EXTENDED RELEASE | 13.2 mg | MDE Replacement | ||
| Q3 2021 | POTASSIUM CITRATE | ORAL | POWDER, FOR SOLUTION | 175.00 mg | MDE Replacement | ||
| Q4 2021 | POTASSIUM CITRATE | ORAL | POWDER, FOR SOLUTION | 490 mg | MDE Replacement | ||
| Q3 2021 | POVIDONE K30 | ORAL | TABLET, CHEWABLE, EXTENDED RELEASE | 8.18 mg | MDE Replacement | ||
| Q4 2021 | POVIDONE K30 | ORAL | TABLET, CHEWABLE, EXTENDED RELEASE | 12.28 mg | MDE Replacement | ||
| Q3 2021 | POVIDONE K90 | ORAL | TABLET | 78.00 mg | MDE Replacement | ||
| Q4 2021 | POVIDONE K90 | ORAL | TABLET | 525 mg | MDE Replacement | ||
| Q3 2021 | POWDERED CELLULOSE | ORAL | TABLET | 560.00 mg | MDE Replacement | ||
| Q4 2021 | POWDERED CELLULOSE | ORAL | TABLET | 1582.4 mg | MDE Replacement | ||
| Q3 2021 | POWDERED CELLULOSE | ORAL | TABLET, FILM COATED | 391.70 mg | MDE Replacement | ||
| Q4 2021 | POWDERED CELLULOSE | ORAL | TABLET, FILM COATED | 391.7 mg | MDE Replacement | ||
| Q3 2021 | PROPYL GALLATE | ORAL | CAPSULE | 2.00 mg | MDE Replacement | ||
| Q4 2021 | PROPYL GALLATE | ORAL | CAPSULE | 4 mg | MDE Replacement | ||
| Q3 2021 | PROPYLENE GLYCOL | BUCCAL | FILM, SOLUBLE | 1.02 mg | MDE Replacement | ||
| Q4 2021 | PROPYLENE GLYCOL | BUCCAL | FILM, SOLUBLE | 4 mg | MDE Replacement | ||
| Q3 2021 | PROPYLENE GLYCOL | INTRAMUSCULAR | INJECTION, SOLUTION | 41.60 %w/v | MDE Replacement | ||
| Q4 2021 | PROPYLENE GLYCOL | INTRAMUSCULAR | INJECTION, SOLUTION | 4000 mg | MDE Replacement | ||
| Q3 2021 | PROPYLENE GLYCOL | ORAL | CAPSULE | 148.31 mg | MDE Replacement | ||
| Q4 2021 | PROPYLENE GLYCOL | ORAL | CAPSULE | 700 mg | MDE Replacement | ||
| Q3 2021 | PROPYLENE GLYCOL | ORAL | TABLET, FILM COATED | 14.62 mg | MDE Replacement | ||
| Q4 2021 | PROPYLENE GLYCOL | ORAL | TABLET, FILM COATED | 154 mg | MDE Replacement | ||
| Q3 2021 | PROPYLENE GLYCOL | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 12.80 mg | MDE Replacement | ||
| Q4 2021 | PROPYLENE GLYCOL | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 19.2 mg | MDE Replacement | ||
| Q3 2021 | PROPYLENE GLYCOL | SUBLINGUAL | SPRAY | 4.50 mg/ 1.00 ml | MDE Replacement | ||
| Q4 2021 | PROPYLENE GLYCOL | SUBLINGUAL | SPRAY | 36 mg | MDE Replacement | ||
| Q3 2021 | PROPYLENE GLYCOL | TOPICAL | GEL, METERED | 35.00 %w/w | MDE Replacement | ||
| Q4 2021 | PROPYLENE GLYCOL | TOPICAL | GEL, METERED | 1225 mg | MDE Replacement | ||
| Q3 2021 | PROPYLENE GLYCOL | VAGINAL | CREAM | 20.00 %w/w | MDE Replacement | ||
| Q4 2021 | PROPYLENE GLYCOL | VAGINAL | CREAM | 400 mg | MDE Replacement | ||
| Q3 2021 | PROPYLPARABEN | BUCCAL | FILM, SOLUBLE | 0.18 mg | MDE Replacement | ||
| Q4 2021 | PROPYLPARABEN | BUCCAL | FILM, SOLUBLE | 0.72 mg | MDE Replacement | ||
| Q3 2021 | PROPYLPARABEN | TOPICAL | GEL | 0.05 %w/w | MDE Replacement | ||
| Q4 2021 | PROPYLPARABEN | TOPICAL | GEL | 1 mg | MDE Replacement | ||
| Q3 2021 | SACCHARIN | ORAL | SYRUP | 3.50 mg/ 5.00 ml | MDE Replacement | ||
| Q4 2021 | SACCHARIN | ORAL | SYRUP | 8 mg | MDE Replacement | ||
| Q3 2021 | SACCHARIN SODIUM | BUCCAL | FILM | 2.99 mg | MDE Replacement | ||
| Q4 2021 | SACCHARIN SODIUM | BUCCAL | FILM | 2.99 mg | MDE Replacement | ||
| Q3 2021 | SACCHARIN SODIUM | BUCCAL | FILM, SOLUBLE | 0.57 mg | MDE Replacement | ||
| Q4 2021 | SACCHARIN SODIUM | BUCCAL | FILM, SOLUBLE | 2 mg | MDE Replacement | ||
| Q3 2021 | SESAME OIL | ORAL | CAPSULE | 162.50 mg | MDE Replacement | ||
| Q4 2021 | SESAME OIL | ORAL | CAPSULE | 2325 mg | MDE Replacement | ||
| Q3 2021 | SILICON DIOXIDE | ORAL | TABLET, CHEWABLE, EXTENDED RELEASE | 1.60 mg | MDE Replacement | ||
| Q4 2021 | SILICON DIOXIDE | ORAL | TABLET, CHEWABLE, EXTENDED RELEASE | 2.4 mg | MDE Replacement | ||
| Q3 2021 | SODIUM ACETATE | INTRAVENOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 125.00 mg | MDE Replacement | ||
| Q4 2021 | SODIUM ACETATE | INTRAVENOUS | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 125 mg | MDE Replacement | ||
| Q3 2021 | SODIUM ACETATE | SUBCUTANEOUS | INJECTION | 0.98%w/v | MDE Replacement | ||
| Q4 2021 | SODIUM ACETATE | SUBCUTANEOUS | INJECTION | 9.8 mg | MDE Replacement | ||
| Q3 2021 | SODIUM BENZOATE | BUCCAL | FILM | 0.96 mg | MDE Replacement | ||
| Q4 2021 | SODIUM BENZOATE | BUCCAL | FILM | 0.96 mg | MDE Replacement | ||
| Q3 2021 | SODIUM BENZOATE | BUCCAL | FILM, SOLUBLE | 0.69 mg | MDE Replacement | ||
| Q4 2021 | SODIUM BENZOATE | BUCCAL | FILM, SOLUBLE | 3 mg | MDE Replacement | ||
| Q3 2021 | SODIUM CARBONATE | ORAL | GRANULE, FOR SUSPENSION | 6.50 mg | MDE Replacement | ||
| Q4 2021 | SODIUM CARBONATE | ORAL | GRANULE, FOR SUSPENSION | 6.5 mg | MDE Replacement | ||
| Q3 2021 | SODIUM CARBONATE | ORAL | TABLET, EXTENDED RELEASE | 30.00 mg | MDE Replacement | ||
| Q4 2021 | SODIUM CARBONATE | ORAL | TABLET, EXTENDED RELEASE | 80 mg | MDE Replacement | ||
| Q3 2021 | SODIUM CHLORIDE | EPIDURAL | INJECTION | 24.00 %w/v | MDE Replacement | ||
| Q4 2021 | SODIUM CHLORIDE | EPIDURAL | INJECTION | 583.62 mg | MDE Replacement | ||
| Q3 2021 | SODIUM CHLORIDE | EPIDURAL | INJECTION, SOLUTION | 0.90 %w/v | MDE Replacement | ||
| Q4 2021 | SODIUM CHLORIDE | EPIDURAL | INJECTION, SOLUTION | 216.65 mg | MDE Replacement | ||
| Q3 2021 | SODIUM CHLORIDE | INTRACARDIAC | INJECTION | 0.70 %w/v | MDE Replacement | ||
| Q4 2021 | SODIUM CHLORIDE | INTRACARDIAC | INJECTION | 63 mg | MDE Replacement | ||
| Q3 2021 | SODIUM CHLORIDE | INTRATHECAL | INJECTION, SOLUTION | 0.90 %w/v | MDE Replacement | ||
| Q4 2021 | SODIUM CHLORIDE | INTRATHECAL | INJECTION, SOLUTION | 122.4 mg | MDE Replacement | ||
| Q3 2021 | SODIUM CHLORIDE | ORAL | CAPSULE, EXTENDED RELEASE | 20.72 mg | MDE Replacement | ||
| Q4 2021 | SODIUM CHLORIDE | ORAL | CAPSULE, EXTENDED RELEASE | 41.44 mg | MDE Replacement | ||
| Q3 2021 | SODIUM CHLORIDE | PARENTERAL | INJECTION | 24.00 %w/v | MDE Replacement | ||
| Q4 2021 | SODIUM CHLORIDE | PARENTERAL | INJECTION | 583.62 mg | MDE Replacement | ||
| Q3 2021 | SODIUM HYDROXIDE | ORAL | TABLET, ORALLY DISINTEGRATING | 0.16 mg | MDE Replacement | ||
| Q4 2021 | SODIUM HYDROXIDE | ORAL | TABLET, ORALLY DISINTEGRATING | 0.62 mg | MDE Replacement | ||
| Q3 2021 | SODIUM LAURYL SULFATE | ORAL | TABLET, CHEWABLE, EXTENDED RELEASE | 0.30 mg | MDE Replacement | ||
| Q4 2021 | SODIUM LAURYL SULFATE | ORAL | TABLET, CHEWABLE, EXTENDED RELEASE | 0.6 mg | MDE Replacement | ||
| Q3 2021 | SODIUM LAURYL SULFATE | VAGINAL | CREAM | 0.33 %w/w | MDE Replacement | ||
| Q4 2021 | SODIUM LAURYL SULFATE | VAGINAL | CREAM | 12 mg | MDE Replacement | ||
| Q3 2021 | SODIUM OLEATE | INTRAVENOUS | INJECTION, EMULSION | 0.48 %w/v | MDE Replacement | ||
| Q4 2021 | SODIUM OLEATE | INTRAVENOUS | INJECTION, EMULSION | 90 mg | MDE Replacement | ||
| Q3 2021 | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | INTRA-ARTICULAR | INJECTION | 0.71 %w/v | MDE Replacement | ||
| Q4 2021 | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | INTRA-ARTICULAR | INJECTION | 28.4 mg | MDE Replacement | ||
| Q3 2021 | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | INTRALESIONAL | INJECTION | 0.71 %w/v | MDE Replacement | ||
| Q4 2021 | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | INTRALESIONAL | INJECTION | 28.4 mg | MDE Replacement | ||
| Q3 2021 | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | NASAL | SPRAY, METERED | 6.48 mg/ 1.00 ml | MDE Replacement | ||
| Q4 2021 | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | NASAL | SPRAY, METERED | 7.1 mg | MDE Replacement | ||
| Q3 2021 | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | ORAL | TABLET, EXTENDED RELEASE | 110.00 mg | MDE Replacement | ||
| Q4 2021 | SODIUM PHOSPHATE, DIBASIC, ANHYDROUS | ORAL | TABLET, EXTENDED RELEASE | 210 mg | MDE Replacement | ||
| Q3 2021 | SODIUM PHOSPHATE, MONOBASIC | BUCCAL | FILM, SOLUBLE | 0.76 mg | MDE Replacement | ||
| Q4 2021 | SODIUM PHOSPHATE, MONOBASIC | BUCCAL | FILM, SOLUBLE | 3 mg | MDE Replacement | ||
| Q3 2021 | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | INTRA-ARTICULAR | INJECTION | 0.34 %w/v | MDE Replacement | ||
| Q4 2021 | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | INTRA-ARTICULAR | INJECTION | 13.6 mg | MDE Replacement | ||
| Q3 2021 | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | INTRALESIONAL | INJECTION | 0.68 %w/v | MDE Replacement | ||
| Q4 2021 | SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | INTRALESIONAL | INJECTION | 13.6 mg | MDE Replacement | ||
| Q3 2021 | SODIUM PHOSPHATE, TRIBASIC | BUCCAL | FILM, SOLUBLE | 0.76 mg | MDE Replacement | ||
| Q4 2021 | SODIUM PHOSPHATE, TRIBASIC | BUCCAL | FILM, SOLUBLE | 3.04 mg | MDE Replacement | ||
| Q3 2021 | SODIUM POLYSTYRENE SULFONATE | ORAL | TABLET, CHEWABLE, EXTENDED RELEASE | 83.18 mg | MDE Replacement | ||
| Q4 2021 | SODIUM POLYSTYRENE SULFONATE | ORAL | TABLET, CHEWABLE, EXTENDED RELEASE | 124.78 mg | MDE Replacement | ||
| Q3 2021 | SORBIC ACID | ORAL | TABLET, FILM COATED | 0.94 mg | MDE Replacement | ||
| Q4 2021 | SORBIC ACID | ORAL | TABLET, FILM COATED | 5 mg | MDE Replacement | ||
| Q3 2021 | SORBIC ACID | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 0.40 mg | MDE Replacement | ||
| Q4 2021 | SORBIC ACID | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 0.8 mg | MDE Replacement | ||
| Q3 2021 | SORBITAN MONOOLEATE | ORAL | TABLET | 1.70 mg | MDE Replacement | ||
| Q4 2021 | SORBITAN MONOOLEATE | ORAL | TABLET | 6.27 mg | MDE Replacement | ||
| Q3 2021 | SORBITAN MONOOLEATE | ORAL | TABLET, FILM COATED | 1.70 mg | MDE Replacement | ||
| Q4 2021 | SORBITAN MONOOLEATE | ORAL | TABLET, FILM COATED | 12 mg | MDE Replacement | ||
| Q3 2021 | SORBITAN MONOOLEATE | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 1.00 mg | MDE Replacement | ||
| Q4 2021 | SORBITAN MONOOLEATE | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 2 mg | MDE Replacement | ||
| Q3 2021 | STARCH | ORAL | TABLET | 1000.00 mg | MDE Replacement | ||
| Q4 2021 | STARCH | ORAL | TABLET | 2440 mg | MDE Replacement | ||
| Q3 2021 | STARCH, POTATO | ORAL | TABLET | 80.59 mg | MDE Replacement | ||
| Q4 2021 | STARCH, POTATO | ORAL | TABLET | 458.4 mg | MDE Replacement | ||
| Q3 2021 | STEARIC ACID | ORAL | TABLET, EXTENDED RELEASE | 187.50 mg | MDE Replacement | ||
| Q4 2021 | STEARIC ACID | ORAL | TABLET, EXTENDED RELEASE | 200 mg | MDE Replacement | ||
| Q3 2021 | STEARIC ACID | ORAL | TABLET, FILM COATED | 22.00 mg | MDE Replacement | ||
| Q4 2021 | STEARIC ACID | ORAL | TABLET, FILM COATED | 176 mg | MDE Replacement | ||
| Q3 2021 | STEARYL ALCOHOL | VAGINAL | CREAM | 8.50 %w/w | MDE Replacement | ||
| Q4 2021 | STEARYL ALCOHOL | VAGINAL | CREAM | 280 mg | MDE Replacement | ||
| Q3 2021 | STYRENE/ISOPRENE/STYRENE BLOCK COPOLYMER | TOPICAL | SYSTEM | 519.75 mg | MDE Replacement | ||
| Q4 2021 | STYRENE/ISOPRENE/STYRENE BLOCK COPOLYMER | TOPICAL | SYSTEM | 519.75 mg | MDE Replacement | ||
| Q3 2021 | SUCCINIC ACID | ORAL | POWDER, FOR SUSPENSION | 1.00 mg | MDE Replacement | ||
| Q4 2021 | SUCCINIC ACID | ORAL | POWDER, FOR SUSPENSION | 5.01 mg | MDE Replacement | ||
| Q3 2021 | SUCRALOSE | ORAL | POWDER, FOR SOLUTION | 41.40 mg | MDE Replacement | ||
| Q4 2021 | SUCRALOSE | ORAL | POWDER, FOR SOLUTION | 82.6 mg | MDE Replacement | ||
| Q3 2021 | SUCRALOSE | ORAL | SOLUTION | 230.00 mg | MDE Replacement | ||
| Q4 2021 | SUCRALOSE | ORAL | SOLUTION | 800 mg | MDE Replacement | ||
| Q3 2021 | SUCROSE | INTRAVENOUS | INJECTION, EMULSION | 5.40 %w/v | MDE Replacement | ||
| Q4 2021 | SUCROSE | INTRAVENOUS | INJECTION, EMULSION | 970 mg | MDE Replacement | ||
| Q3 2021 | TALC | ORAL | TABLET, CHEWABLE, EXTENDED RELEASE | 12.00 mg | MDE Replacement | ||
| Q4 2021 | TALC | ORAL | TABLET, CHEWABLE, EXTENDED RELEASE | 18 mg | MDE Replacement | ||
| Q3 2021 | TALC | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 30.00 mg | MDE Replacement | ||
| Q4 2021 | TALC | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 60 mg | MDE Replacement | ||
| Q3 2021 | TARTARIC ACID | ORAL | TABLET, FOR SUSPENSION | 7.00 mg | MDE Replacement | ||
| Q4 2021 | TARTARIC ACID | ORAL | TABLET, FOR SUSPENSION | 28 mg | MDE Replacement | ||
| Q3 2021 | TERT-BUTYLHYDROQUINONE | VAGINAL | CREAM | 0.02 %w/w | MDE Replacement | ||
| Q4 2021 | TERT-BUTYLHYDROQUINONE | VAGINAL | CREAM | 0.8 mg | MDE Replacement | ||
| Q3 2021 | TITANIUM DIOXIDE | BUCCAL | FILM, SOLUBLE | 2.78 mg | MDE Replacement | ||
| Q4 2021 | TITANIUM DIOXIDE | BUCCAL | FILM, SOLUBLE | 2.78 mg | MDE Replacement | ||
| Q3 2021 | TITANIUM DIOXIDE | ORAL | SUSPENSION | 75 mg | Correction | ||
| Q4 2021 | TITANIUM DIOXIDE | ORAL | SUSPENSION | 80 mg | Correction | ||
| Q3 2021 | TITANIUM DIOXIDE | ORAL | TABLET, FILM COATED | 24.23 mg | MDE Replacement | ||
| Q4 2021 | TITANIUM DIOXIDE | ORAL | TABLET, FILM COATED | 36 mg | MDE Replacement | ||
| Q3 2021 | TRIACETIN | ORAL | TABLET, CHEWABLE, EXTENDED RELEASE | 1.36 mg | MDE Replacement | ||
| Q4 2021 | TRIACETIN | ORAL | TABLET, CHEWABLE, EXTENDED RELEASE | 2.04 mg | MDE Replacement | ||
| Q3 2021 | TRIETHYL CITRATE | ORAL | GRANULE, FOR SUSPENSION | 6.94 mg | MDE Replacement | ||
| Q4 2021 | TRIETHYL CITRATE | ORAL | GRANULE, FOR SUSPENSION | 6.94 mg | MDE Replacement | ||
| Q3 2021 | TRISODIUM CITRATE DIHYDRATE | INTRACARDIAC | INJECTION | 0.21 %w/v | MDE Replacement | ||
| Q4 2021 | TRISODIUM CITRATE DIHYDRATE | INTRACARDIAC | INJECTION | 18.63 mg | MDE Replacement | ||
| Q3 2021 | TRISODIUM CITRATE DIHYDRATE | SUBCUTANEOUS | INJECTION | 0.63 %w/v | MDE Replacement | ||
| Q4 2021 | TRISODIUM CITRATE DIHYDRATE | SUBCUTANEOUS | INJECTION | 18.63 mg | MDE Replacement | ||
| Q3 2021 | TROLAMINE | TOPICAL | GEL, METERED | 1.00 %w/w | MDE Replacement | ||
| Q4 2021 | TROLAMINE | TOPICAL | GEL, METERED | 19.25 mg | MDE Replacement | ||
| Q3 2021 | TROMETHAMINE | ORAL | CAPSULE | 15.00 mg | MDE Replacement | ||
| Q4 2021 | TROMETHAMINE | ORAL | CAPSULE | 30 mg | MDE Replacement | ||
| Q3 2021 | VANILLIN | ORAL | TABLET | 1.50 mg | MDE Replacement | ||
| Q4 2021 | VANILLIN | ORAL | TABLET | 4.5 mg | MDE Replacement | ||
| Q3 2021 | VANILLIN | ORAL | TABLET, FILM COATED | 0.94 mg | MDE Replacement | ||
| Q4 2021 | VANILLIN | ORAL | TABLET, FILM COATED | 5 mg | MDE Replacement | ||
| Q3 2021 | VANILLIN | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 0.80 mg | MDE Replacement | ||
| Q4 2021 | VANILLIN | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 0.8 mg | MDE Replacement | ||
| Q3 2021 | VEGETABLE OIL, HYDROGENATED | ORAL | TABLET | 40.00 mg | MDE Replacement | ||
| Q4 2021 | VEGETABLE OIL, HYDROGENATED | ORAL | TABLET | 42 mg | MDE Replacement | ||
| Q3 2021 | WHITE PETROLATUM | TOPICAL | CREAM | 15.00 %w/w | MDE Replacement | ||
| Q4 2021 | WHITE PETROLATUM | TOPICAL | CREAM | 798 mg | MDE Replacement | ||
| Q3 2021 | XANTHAN GUM | ORAL | GRANULE, FOR SUSPENSION | 259.40 mg | MDE Replacement | ||
| Q4 2021 | XANTHAN GUM | ORAL | GRANULE, FOR SUSPENSION | 450 mg | MDE Replacement | ||
| Q3 2021 | XANTHAN GUM | ORAL | TABLET, CHEWABLE, EXTENDED RELEASE | 4.00 mg | MDE Replacement | ||
| Q4 2021 | XANTHAN GUM | ORAL | TABLET, CHEWABLE, EXTENDED RELEASE | 6 mg | MDE Replacement | ||
| Q3 2021 | XANTHAN GUM | TOPICAL | CREAM | 0.75 %w/w | MDE Replacement | ||
| Q4 2021 | XANTHAN GUM | TOPICAL | CREAM | 45.6 mg | MDE Replacement | ||
| Q3 2021 | XYLITOL | BUCCAL | GUM, CHEWING | 506.13 mg | MDE Replacement | ||
| Q4 2021 | XYLITOL | BUCCAL | GUM, CHEWING | 9542.6 mg | MDE Replacement | ||
| Q3 2021 | XYLITOL | SUBLINGUAL | SPRAY | 2.70 mg/ 1.00 ml | MDE Replacement | ||
| Q4 2021 | XYLITOL | SUBLINGUAL | SPRAY | 21.6 mg | MDE Replacement | ||
| Q4 2021 | ACETYLTRIBUTYL CITRATE | TOPICAL | SPONGE | 5.40 %w/w | Deletion | ||
| Q4 2021 | ANHYDROUS TRISODIUM CITRATE | ORAL | SYRUP | 7.95 mg/ 5.00 ml | Deletion | ||
| Q4 2021 | BORIC ACID | ORAL | SOLUTION/ DROPS | 15.00 mg/ 1.00 ml | Deletion | ||
| Q4 2021 | EDETATE DISODIUM | ORAL | SOLUTION/ DROPS | 1.00 mg/ 1.00 ml | Deletion | ||
| Q4 2021 | FD&C BLUE NO. 1 | TOPICAL | SPONGE | 0.01 %w/w | Deletion | ||
| Q4 2021 | FD&C YELLOW NO. 5 | TOPICAL | SPONGE | 0.06 %w/w | Deletion | ||
| Q4 2021 | HYDROGENATED SOYBEAN LECITHIN | INTRAVENOUS | INJECTION, SUSPENSION, LIPOSOMAL | 0.96 %w/v | Deletion | ||
| Q4 2021 | HYDROLYZED SOY PROTEIN (ENZYMATIC; 2000 MW) | INTRAVENOUS | INJECTABLE, LIPOSOMAL | 0.96 %w/v | Deletion | ||
| Q4 2021 | HYPROMELLOSE | NASAL | SPRAY, METERED | 1.00 mg/ 1.00 ml | Deletion | ||
| Q4 2021 | HYPROMELLOSE 2208 (100 MPA.S) | BUCCAL | TABLET, DELAYED RELEASE | 17.25 mg | Deletion | ||
| Q4 2021 | HYPROMELLOSE 2208 (100000 MPA.S) | ORAL | TABLET, FILM COATED | 536.80 mg | Deletion | ||
| Q4 2021 | HYPROMELLOSE PHTHALATE | ORAL | CAPSULE | 48.10 mg | Deletion | ||
| Q4 2021 | HYPROMELLOSE PHTHALATE | ORAL | TABLET, FILM COATED | 23.10 mg | Deletion | ||
| Q4 2021 | HYPROMELLOSE PHTHALATE | ORAL | TABLET, DELAYED RELEASE | 16.42 mg | Deletion | ||
| Q4 2021 | ISOOCTYL ACRYLATE/ACRYLAMIDE/VINYL ACETATE COPOLYMER, KOLLIDON VA 64 POLYMER | ORAL | TABLET, FILM COATED | 53.00 mg | Deletion | ||
| Q4 2021 | MAGNESIUM STEARATE | BUCCAL | TABLET, DELAYED RELEASE | 0.58 mg | 1 mg | Deletion | |
| Q4 2021 | METHYLCELLULOSE | VAGINAL | TABLET | 102.00 mg | Deletion | ||
| Q4 2021 | MICROCRYSTALLINE CELLULOSE | BUCCAL | TABLET, DELAYED RELEASE | 18.04 mg | Deletion | ||
| Q4 2021 | MILK PROTEIN CONCENTRATE | BUCCAL | TABLET, DELAYED RELEASE | 23.00 mg | 23 mg | Deletion | |
| Q4 2021 | OPADRY YS-1-14142 PINK | ORAL | TABLET, FILM COATED, EXTENDED RELEASE | 16.00 mg | 26.8 mg | Deletion | |
| Q4 2021 | OPADRY YS-2-19114A CLEAR | ORAL | TABLET, EXTENDED RELEASE | 1.50 mg | Deletion | ||
| Q4 2021 | OPALUX AS 2553 ORANGE | ORAL | TABLET | NA | Deletion | ||
| Q4 2021 | OPALUX AS 5034 RED | ORAL | TABLET, COATED | 0.02 mg | Deletion | ||
| Q4 2021 | POLYETHYLENE GLYCOL 6000 | VAGINAL | INSERT | 0.10 mg | Deletion | ||
| Q4 2021 | POLYOXYL 35 CASTOR OIL | ORAL | SOLUTION/ DROPS | 50.00 mg/ 1.00 ml | Deletion | ||
| Q4 2021 | POLYVINYL ALCOHOL | VAGINAL | TABLET | 20.60 mg | Deletion | ||
| Q4 2021 | POVIDONE K27 | ORAL | TABLET | 26.60 mg | Deletion | ||
| Q4 2021 | POVIDONE K30 | BUCCAL | TABLET, DELAYED RELEASE | 0.50 mg | 0.5 mg | Deletion | |
| Q4 2021 | SILICON DIOXIDE | BUCCAL | TABLET, DELAYED RELEASE | 0.46 mg | Deletion | ||
| Q4 2021 | SORBIC ACID | ORAL | SOLUTION/ DROPS | 2.00 mg/ 1.00 ml | Deletion | ||
| Q4 2021 | TRISODIUM HEDTA | TOPICAL | SPONGE | 0.01 %w/w | Deletion | ||
| Q4 2021 | TROMETHAMINE | ORAL | SOLUTION/ DROPS | 7.60 mg/ 1.00 ml | Deletion |
FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly
Data Through: September 30, 2021
Database Last Updated: October 21, 2021
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English